DHODH inhibitor polymorphs
Through the development of stable crystalline polymorphs of 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)niacin, existing DHODH inhibitors are solved in the treatment of viral diseases and their own Stability and pharmacokinetic problems in immune diseases achieve more efficient and safe therapeutic effects.
Patent Information
- Application Number
- CN202380032726.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-13
- Filing Date
- 2023-02-02
- Publication Date
- 2024-11-19
AI Technical Summary
Existing DHODH inhibitors have stability and pharmacokinetic problems in the treatment of viral and autoimmune diseases, affecting the therapeutic effect and patient safety.
A stable crystalline polymorph of 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)niacin was developed to characterize its specific peak position and intensity by X-ray powder diffraction pattern. , ensures the physical and chemical stability of the drug, and combines pharmaceutically acceptable excipients, diluents or carriers to form suitable formulation forms.
It improves the stability and bioavailability of drugs, reduces side effects on healthy cells, enhances the selective killing ability of target cells, and improves the therapeutic effect and patient quality of life.
Smart Images

Figure BDA0005072440930000121 
Figure BDA0005072440930000131 
Figure BDA0005072440930000321
Abstract
Description
Technical Field
[0001] The present disclosure relates to physical forms of DHODH inhibitors (such as stable crystalline forms thereof) and compositions comprising the same. Also provided are uses of the physical forms (such as polymorphs) or compositions in treatment (such as treatment of viral diseases or autoimmune diseases or disorders). Background Art
[0002] 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid (farudodstat, formerly known as ASLAN003) is a next generation DHODH inhibitor.
[0003] Dihydroorotate dehydrogenase (DHODH) is an enzyme that catalyzes the fourth step in the pyrimidine biosynthetic pathway, i.e., the conversion of dihydroorotate to orotate, with electron transfer to ubiquinone (cofactor Q) via a flavin mononucleotide intermediate (Loffler Mol Cell Biochem, 1997). Compared to parasites (Plasmodium falciparum) (McRobert et al., Mol Biochem Parasitol 2002) and bacteria (E. coli) that exclusively have this de novo pathway as a source of pyrimidines, mammalian cells have an additional salvage pathway.
[0004] During homeostatic proliferation, salvage pathways independent of DHODH appear to be sufficient for the cell to supply pyrimidine bases. However, in cells with high turnover, a de novo pathway is required to proliferate. In these cells, DHODH inhibition stops cell cycle progression and ultimately stops cell proliferation by inhibiting DNA and RNA synthesis (Breedveld FCAnn Rheum Dis2000).
[0005] There are some suggestions that inhibition of mitochondrial cytochrome bcl, a component of complex III of the electron transport chain, leads to activation of p53, followed by induction of apoptosis. The mitochondrial respiratory chain is coupled to the de novo pyrimidine biosynthetic pathway via the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH).
[0006] Therefore, the administration of fafostat to cells with a high metabolic burden can inhibit the normal function of cells and promote apoptosis / removal of these cells by the body's natural mechanisms. The latter can be used for cells and cancer cells infected by viruses. In addition, fafostat has the activity of combating the root causes of autoimmune diseases (i.e., abnormal T cells and / or B cells), which unexpectedly transforms into a broad spectrum of activity against autoimmune diseases in vivo, with minimal off-target effects, particularly hepatotoxicity.
[0007] Compared to other existing DHODH inhibitors, Faroxetine has a high affinity for DHODH, is well tolerated and delivers excellent results to patients. It has the ability to positively impact the patient's quality of life to control the disease state and halt its progression and / or alleviate the disease. Advantageously, healthy cells with a lower metabolic burden are generally unaffected by the treatment. The balanced nature of the treatment is extremely beneficial to patients.
[0008] Polymorphs are crystals of the same molecule with different physical properties resulting from different organizations of the molecules within the crystal lattice. Ostwarld pointed out in 1899 that "almost every substance can exist in two or more solid phases, provided the experimental conditions are suitable".
[0009] Different spatial structures lead to different physical properties, which can affect various parameters: for example, compressibility and density, manufacturability, storability, physical stability, chemical stability, thermal stability, melting point, grindability, rheological properties of powders, hygroscopicity, solubility, dissolution rate, in vivo pharmacology, etc.
[0010] These properties can then affect drug-related parameters, such as the convenience of preparing formulations and / or superior pharmacokinetics. Therefore, it is most important to select suitable polymorphs in drug development. In particular, it is important to identify the stable drug polymorphs (DSP polymorphs) of advantage. For example, for ranitidine, this is form 4.
[0011] The present inventors have identified a polymorph of farostat DSP having excellent stability and good pharmacological function. Summary of the invention
[0012] The disclosure is summarized as follows:
[0013] 1. A polymorph of the DHODH inhibitor 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid, such as a crystalline polymorph, characterized by an X-ray powder diffraction pattern comprising peaks corresponding to 2-theta angles at approximately the following positions: 9.129±0.1, 17.375±0.1, 20.708±0.1, 25.274±0.1, 26.488±0.1, and 29.041±0.1.
[0014] 2. The polymorph of paragraph 1, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1 and 30.893±0.1.
[0015] 3. The polymorph of paragraph 2, wherein the pattern comprises a peak at 13.686±0.1, for example having a relative intensity of about 14%.
[0016] 4. The polymorph of paragraph 2 or 3, wherein the pattern comprises a peak at 14.159±0.1, for example having a relative intensity of about 16%.
[0017] 5. The polymorph as described in any of paragraphs 2 to 4, wherein the pattern comprises a peak at 19.900±0.1, for example with a relative intensity of about 11.5%.
[0018] 6. The polymorph as described in any of paragraphs 2 to 5, wherein the pattern comprises a peak at 21.431±0.1, for example with a relative intensity of about 14%.
[0019] 7. The polymorph as described in any of paragraphs 2 to 6, wherein the pattern comprises a peak at 22.750±0.1, for example with a relative intensity of about 16.5%.
[0020] 8. The polymorph as described in any of paragraphs 2 to 7, wherein the pattern comprises a peak at 25.607±0.1, for example with a relative intensity of about 12%.
[0021] 9. The polymorph as described in any of paragraphs 2 to 8, wherein the pattern comprises a peak at 30.893±0.1, for example with a relative intensity of about 15%.
[0022] 10. The polymorph described in any of paragraphs 1 or 9, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 12.313±0.1, 13.223±0.1, 16.477±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1 and 30.612±0.1.
[0023] 11. The polymorph of paragraph 10, wherein the X-ray powder diffraction pattern further comprises a peak at 12.313±0.1, for example having a relative intensity of about 10.5%.
[0024] 12. The polymorph of paragraph 10 or 11, wherein the X-ray powder diffraction pattern further comprises a peak at 13.223±0.1, for example with a relative intensity of about 7%.
[0025] 13. The polymorph as described in any of paragraphs 10 to 12, wherein the X-ray powder diffraction pattern further comprises a peak at 16.477±0.1, for example with a relative intensity of about 10.5%.
[0026] 14. The polymorph as described in any of paragraphs 10 to 13, wherein the X-ray powder diffraction pattern further comprises a peak at 18.167±0.1, for example with a relative intensity of about 7.0%.
[0027] 15. The polymorph as described in any of paragraphs 10 to 14, wherein the X-ray powder diffraction pattern further comprises a peak at 22.146±0.1, for example with a relative intensity of about 8%.
[0028] 16. The polymorph as described in any of paragraphs 10 to 15, wherein the X-ray powder diffraction pattern further comprises a peak at 23.418±0.1, for example with a relative intensity of about 10%.
[0029] 17. The polymorph as described in any of paragraphs 10 to 16, wherein the X-ray powder diffraction pattern further comprises a peak at 25.885±0.1, for example with a relative intensity of about 7.5%.
[0030] 18. The polymorph as described in any of paragraphs 10 to 17, wherein the X-ray powder diffraction pattern further comprises a peak at 27.219±0.1, for example with a relative intensity of about 9.5%.
[0031] 19. The polymorph as described in any of paragraphs 10 to 18, wherein the X-ray powder diffraction pattern further comprises a peak at 30.612±0.1, for example with a relative intensity of about 7.5%.
[0032] 20. The polymorph described in any of paragraphs 1 to 19, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1 and 39.115±0.1.
[0033] 21. The polymorph of paragraph 20, wherein the X-ray powder diffraction pattern further comprises a peak at 10.645 ± 0.1, for example having a relative intensity of about 4.5%.
[0034] 22. The polymorph of paragraph 20 or 21, wherein the X-ray powder diffraction pattern further comprises a peak at 27.453±0.1, for example having a relative intensity of about 5.6%.
[0035] 23. The polymorph as described in any of paragraphs 20 to 22, wherein the X-ray powder diffraction pattern further comprises a peak at 29.762±0.1, for example with a relative intensity of about 4.5%.
[0036] 24. The polymorph as described in any of paragraphs 20 to 23, wherein the X-ray powder diffraction pattern further comprises a peak at 31.743±0.1, for example with a relative intensity of about 5%.
[0037] 25. The polymorph of any of paragraphs 20 to 23, wherein the X-ray powder diffraction pattern further comprises a peak at 39.115±0.1, for example with a relative intensity of about 6%.
[0038] 26. A polymorph as described in any of the preceding paragraphs, wherein Figure 2 The X-ray powder diffraction pattern shown in .
[0039] 27. The polymorph of any of paragraphs 1 to 26, wherein the average particle diameter in the polymorph is in the range of 5 to 15 microns, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15.
[0040] 28. The polymorph of paragraph 27, wherein 10% (D10) of the particles in the polymorph have a diameter in the range of 0.5 to 5 microns (e.g., 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, or 5).
[0041] 29. The polymorph of paragraph 27 or 28, wherein 50% of the particles in the polymorph have a diameter in the range of 1 to 10 microns (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10).
[0042] 30. The polymorph of any of paragraphs 27 to 29, wherein 90% of the particles in the polymorph have a diameter in the range of 5 to 50 microns (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, or 50).
[0043] 31. The polymorph of any of paragraphs 1 to 26, wherein the average particle diameter in the polymorph is within 147 to 157 microns, for example, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156 or 157.
[0044] 32. The polymorph of paragraph 31, wherein 10% of the particles in the polymorph have a diameter in the range of 20 to 40 microns (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 microns, such as 32 microns).
[0045] 33. The polymorph of paragraphs 31 or 32, wherein 50% of the particles in the polymorph have a diameter in the range of 150 to 170 microns (e.g., 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169 or 170, such as 161 microns).
[0046] 34. The polymorph of any of paragraphs 31 to 33, wherein 90% of the particles in the polymorph have a diameter in the range of 230 to 245 microns (e.g., 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, such as 238 microns).
[0047] 35. A composition comprising a polymorph as described in any of the preceding paragraphs and a pharmaceutically acceptable excipient, diluent or carrier.
[0048] 36. A polymorph according to any one of paragraphs 1 to 34 or a composition according to paragraph 35 for use in treating, for example, cancer, such as a blood cancer.
[0049] 37. A polymorph or composition for use as described in paragraph 36, wherein the treatment is for a viral disease or an autoimmune disease.
[0050] 38. A polymorph or composition for use as described in paragraph 37, wherein the virus is selected from the group comprising: dengue (such as serotype 1, 2, 3 or 4), Zika, Chikungunya and SARS-CoV-2.
[0051] 39. A polymorph or composition for use according to paragraph 37, wherein the autoimmune disease is selected from the group comprising multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease (such as ulcerative colitis and Crohn's disease).
[0052] 40. A polymorph or composition for use as described in paragraph 37, wherein the autoimmune disease is an autoimmune skin disease, for example selected from the group comprising: vitiligo, alopecia, atopic dermatitis, Behcet's disease, dermatitis herpetiformis, dermatomyositis, lichen planus, linear IgA disease, cutaneous lupus, morphea / scleroderma, ocular cicatricial pemphigoid, pemphigoid (such as bullous pemphigoid or gestational pemphigoid), pemphigus (such as pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, IgA pemphigus, pemphigus vegetative or paraneoplastic pemphigus), vasculitis, epidermolysis bullosa acquisita, psoriasis and vesiculobullous dermatosis.
[0053] 41. A polymorph or composition for use as described in paragraph 40, wherein the autoimmune skin disease is selected from the group comprising: vitiligo, such as segmental or non-segmental vitiligo; and alopecia, such as diffuse alopecia areata, monolocalized alopecia areata, creeping alopecia areata, barbaric alopecia, alopecia totalis or universalis.
[0054] 42. Use of a polymorph as described in any one of paragraphs 1 to 34 or a composition as described in paragraph 35 in the manufacture of a medicament for treating a viral infection or an autoimmune disease.
[0055] 43. The use according to paragraph 42, wherein the virus is selected from the group comprising dengue (such as serotype 1, 2, 3 or 4), Zika, Chikungunya and SARS-CoV-2.
[0056] 44. The use according to paragraph 42, wherein the autoimmune disease is selected from the group comprising: multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease (such as ulcerative colitis and Crohn's disease).
[0057] 45. The use according to paragraph 42, wherein the autoimmune disease is an autoimmune skin disease, for example, selected from the group comprising: vitiligo, alopecia, atopic dermatitis, Behcet's disease, dermatitis herpetiformis, dermatomyositis, lichen planus, linear IgA disease, cutaneous lupus, morphea / scleroderma, ocular cicatricial pemphigoid, pemphigoid (such as bullous pemphigoid or gestational pemphigoid), pemphigus (such as pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, IgA pemphigus, pemphigus vegetative or paraneoplastic pemphigus), vasculitis, epidermolysis bullosa acquisita, psoriasis and bullous dermatoses.
[0058] 46. The use according to paragraph 45, wherein the autoimmune skin disease is selected from the group comprising: vitiligo, such as segmental or non-segmental vitiligo; and alopecia, such as diffuse alopecia areata, monolocalized alopecia areata, creeping alopecia areata, barbaric alopecia, alopecia totalis or universalis.
[0059] 47. A method of treating a viral infection or an autoimmune disease comprising administering to a subject in need thereof a therapeutically effective amount of a polymorph of any one of paragraphs 1 to 34 or a composition of paragraph 35.
[0060] 48. The method of paragraph 47, wherein the virus is selected from the group comprising dengue (such as serotype 1, 2, 3 or 4), Zika, Chikungunya and SARS-CoV-2.
[0061] 49. The method of paragraph 47, wherein the autoimmune disease is selected from the group comprising: multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease (such as ulcerative colitis and Crohn's disease).
[0062] 50. The method of paragraph 47, wherein the autoimmune disease is an autoimmune skin disease, for example selected from the group comprising: vitiligo, alopecia, atopic dermatitis, Behcet's disease, dermatitis herpetiformis, dermatomyositis, lichen planus, linear IgA disease, cutaneous lupus, morphea / scleroderma, ocular cicatricial pemphigoid, pemphigoid (such as bullous pemphigoid or gestational pemphigoid), pemphigus (such as pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, IgA pemphigus, pemphigus vegetative or paraneoplastic pemphigus), vasculitis, epidermolysis bullosa acquisita, psoriasis and bullous dermatoses.
[0063] 51. The method of paragraph 50, wherein the autoimmune skin disease is selected from the group comprising: vitiligo, such as segmental or non-segmental vitiligo; and alopecia, such as diffuse alopecia areata, monolocalized alopecia areata, creeping alopecia areata, barbaric alopecia, alopecia totalis, or universalis.
[0064] In one embodiment, the relative intensity of peak 17.375 is about 100%. In one embodiment, the relative intensity of peak 9.129 is about 66%. In one embodiment, the relative intensity of peak 20.708 is about 76%. In one embodiment, the relative intensity of peak 26.488 is about 43%. In one embodiment, the relative intensity of peak 29.041 is about 29%.
[0065] Thus, in one aspect, a stable crystalline polymorph of the DHODH inhibitor 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid is provided, characterized by an X-ray powder diffraction pattern comprising peaks corresponding to 2-theta angles at approximately the following positions: 9.129±0.1, 17.375±0.1, 20.708±0.1, 25.274±0.1, 26.488±0.1, and 29.041±0.1.
[0066] Advantageously, the inventors have confirmed that the crystalline polymorph of 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid (Faloxat) characterized by the above X-ray powder diffraction pattern has a very high stability.
[0067] In one embodiment, the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1 and 30.893±0.1.
[0068] In one embodiment, the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1 and 30.612±0.1.
[0069] In one embodiment, the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1, and 39.115±0.1.
[0070] In one embodiment, the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 14.580±0.1, 28.368±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, and 38.520±0.1.
[0071] In one embodiment, the X-ray powder diffraction pattern comprises (or further comprises) one or more peaks selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1, and 30.612±0.1.
[0072] In one embodiment, the X-ray powder diffraction pattern comprises (or further comprises) the following selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18.16 7±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1, 30.612±0.1, 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1 and 39.115±0.1.
[0073] In one embodiment, the X-ray powder diffraction pattern further comprises the following selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1, 30 one or more peaks in the group consisting of .612±0.1, 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1, 39.115±0.1, 14.580±0.1, 28.368±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, and 38.520±0.1.
[0074] In one embodiment, the X-ray powder diffraction pattern further comprises the following peaks: 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1, and 30.612±0.1.
[0075] In one embodiment, the X-ray powder diffraction pattern further comprises the following peaks: 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18 .167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1, 30.612±0.1, 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1 and 39.115±0.1.
[0076] In one embodiment, the X-ray powder diffraction pattern further comprises the following peaks: 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1, 30.893±0.1, 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1 .1, 30.612±0.1, 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1, 39.115±0.1, 14.580±0.1, 28.368±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1 and 38.520±0.1.
[0077] In one embodiment, the X-ray powder diffraction pattern comprises the following peaks: 9.129±0.1, 10.645±0.1, 12.313±0.1, 13.223±0.1, 13.686±0.1, 14.159±0.1, 14.580±0.1, 16.477±0.1, 17.375±0.1, 18.167±0.1, 19.900±0.1, 20.708±0.1, 21.431±0.1, 22.146±0.1, 22.750±0.1, 23.418±0.1, 23.828±0.1, 25.274±0.1, 25.6 0.1, 25.885±0.1, 26.488±0.1, 27.219±0.1, 27.453±0.1, 28.368±0.1, 29.041±0.1, 29.762±0.1, 30.612±0.1, 30.893±0.1, 31.743±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, 38.520±0.1 and 39.115±0.1.
[0078] In one embodiment, the polymorph is obtained by Figure 2 In one embodiment, the polymorph is characterized by the X-ray powder diffraction (XRPD) pattern shown in Fig.26 The XRPD pattern shown in Figure 1 is characterized.
[0079] In one embodiment, the polymorph is characterized by an XRPD pattern comprising Figure 3 (which shows peaks 1 to 39) one or more (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 or all) peaks listed in. In one embodiment, the polymorph is characterized by an XRPD pattern comprising Figure 3 All peaks listed in .
[0080] In one aspect, a polymorph (such as a crystalline polymorph) of the DHODH inhibitor 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid is provided, which is characterized by an X-ray powder diffraction pattern comprising one or more of the following peaks, wherein the peaks correspond to 2-theta angles at approximately the following positions: 8.9072±0.1, 10.464±0.1, 12.132±0.1, 13.5505±0.1, 13.9897±0.1, 16.3257±0.1, 17.0936±0.1, 17 .2922±0.1, 19.6989±0.1, 20.4996±0.1, 21.225±0.1, 22.0126±0.1, 22.5466±0.1, 22.7501±0.1, 25.121±0.1, 26.3694±0.1, 27.2907±0.1, 28.7305±0.1, 29.3309±0.1, 30.7531±0.1, 31.7095±0.1, 32.9909±0.1 and 34.266±0.1.
[0081] In one embodiment, the polymorph comprises one or more of the following peaks: 8.9072±0.1, 17.0936±0.1, 20.4996±0.1, 25.121±0.1, and 26.3694±0.1. In one embodiment, the polymorph comprises at least the following peaks: 8.9072±0.1, 17.0936±0.1, 20.4996±0.1, 25.121±0.1, and 26.3694±0.1.
[0082] In one embodiment, the polymorph is characterized by an XRPD pattern comprising the following peaks: 8.9072±0.1, 10.464±0.1, 12.132±0.1, 13.5505±0.1, 13.9897±0.1, 16.3257±0.1, 17.0936±0.1, 17.2922±0.1, 19.6989±0.1, 20.4996±0.1, 21.225±0.1, 22.0126±0.1, 22.5466±0.1, 22.7501±0.1, 25.121±0.1, 26.3694±0.1, 27.2907±0.1, 28.7305±0.1, 29.3309±0.1, 30.7531±0.1, 31.7095±0.1, 32.9909±0.1 and 34.266±0.1.
[0083] In one embodiment, the polymorph is obtained by Fig.26 The XRPD pattern shown in Figure 1 is characterized.
[0084] In one embodiment, the polymorph is characterized by an XRPD pattern comprising Fig.43 (which shows peaks 1 to 30) one or more (1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or all) peaks listed in. In one embodiment, the polymorph is characterized by an XRPD pattern comprising Fig.43 All peaks listed in .
[0085] In one embodiment, the polymorph is characterized by an XRPD pattern comprising Fig.43 In one embodiment, the polymorph is characterized by an XRPD pattern comprising: Fig.43 Peaks 1, 2, 3, 4, 5, 6, 7, 8, 12, 13, 14, 15, 16, 17, 20, 22, 23, 24, 25, 27, 28, 29 and 30 listed in.
[0086] In an independent aspect, a polymorph (such as a crystalline polymorph) of the DHODH inhibitor 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid is provided, which is characterized by an X-ray powder diffraction pattern comprising one or more of the following peaks, wherein the peaks correspond to 2-theta angles at approximately the following positions: 9.3112±0.1, 10.2275±0.1, 11.2939±0.1, 11.9453±0.1, 14.3786±0.1, 14.7466±0.1, 16.1054±0.1, 16.561 ±0.1, 17.0456±0.1, 17.6267±0.1, 18.2131±0.1, 18.6757±0.1, 20.5363±0.1, 22.7337±0.1, 23.5524±0.1, 24.0002±0.1, 24.4047±0.1, 24.8923±0.1, 25.2252±0.1, 25.8169±0.1, 27.3981±0.1, 28.1985±0.1, 30.8567±0.1 and 32.9406±0.1.
[0087] In one embodiment, a polymorph (such as a crystalline polymorph) of the DHODH inhibitor 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid is provided, which is characterized by an X-ray powder diffraction pattern comprising the following peaks, and the 2-theta angles corresponding to the peaks are approximately at the following positions: 9.3112±0.1, 10.2275±0.1, 11.2939±0.1, 11.9453±0.1, 14.3786±0.1, 14.7466±0.1, 16.1054±0.1, 16.561±0. 1, 17.0456±0.1, 17.6267±0.1, 18.2131±0.1, 18.6757±0.1, 20.5363±0.1, 22.7337±0.1, 23.5524±0.1, 24.0002±0.1, 24.4047±0.1, 24.8923±0.1, 25.2252±0.1, 25.8169±0.1, 27.3981±0.1, 28.1985±0.1, 30.8567±0.1 and 32.9406±0.1.
[0088] In a separate aspect, a polymorph (such as a crystalline polymorph) of the DHODH inhibitor 2-(3,5-difluoro-3'methoxybiphenyl-4-ylamino)nicotinic acid is provided, which is obtained by Fig.37 The X-ray powder diffraction pattern shown in Figure 2 is characterized.
[0089] In one embodiment, the polymorph is characterized by an XRPD pattern comprising Fig.38 In one embodiment, the polymorph is characterized by an XRPD pattern comprising Fig.38 All peaks listed in .
[0090] In one embodiment, the solid form of the present disclosure is a solvate, for example, a hydrate or a hemihydrate.
[0091] In one embodiment, the polymorph is a crystalline polymorph. In one embodiment, the particles are irregularly shaped. In one embodiment, the particles are regularly shaped, spherical.
[0092] In one embodiment, the compound (API) is ground. Examples of grinding include cone milling, hammer milling.
[0093] In one embodiment, the compound (API) is micronized, for example, to a uniform particle size, such as a D90 of 10 microns or less.
[0094] The primary particle size is affected by temperature. In one embodiment, the primary particle size is formed at 15 to 65 ° C (e.g., 15, 20, 25, 30, 35, 40, 45, 50, 55, 60 or 65 ° C). In one embodiment, the primary particle size is formed at 20 to 60 ° C (such as 20, 25, 30, 35, 40, 45, 50, 55 or 60 ° C). In one embodiment, the primary particle size is formed at 20 to 35 ° C (such as 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 ° C).
[0095] The solvent also affects the primary particle size. In one embodiment, the solvent is one or a combination of those described in the Examples herein.
[0096] Detailed Description
[0097] As used herein, a predominantly stable pharmaceutical polymorph refers to a polymorphic form that, once prepared, becomes the predominant form (e.g., replaces other prior forms) and is suitable for use as a pharmaceutical API (active product ingredient), particularly the polymorphs described in the examples and figures herein.
[0098] 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid (referred to herein as farostat or ASLAN003) has the structure:
[0099]
[0100] As used herein, the term "polymorph" refers to a specific crystal form of a chemical compound, which may exist in the solid state in more than one crystal form. The crystal form of a compound contains constituent molecules arranged in an ordered repeating pattern that extend in all three spatial dimensions (in contrast, an amorphous solid form does not have long-range order in the position of the molecule). Different polymorphs of a compound have different arrangements of atoms and or molecules in its crystal structure. When the compound is a biologically active compound, the difference in crystal structure may result in different polymorphs with different chemical, physical and biological properties. The properties that may be affected include crystal shape, density, hardness, color, chemical stability, melting point, water absorption, suspension, dissolution rate and bioavailability. Thus, a specific polymorph may have a property that makes it more favorable relative to another polymorph of the same compound. It should be noted that it is impossible to predict whether the solid state of a compound exists in more than one polymorph and it is impossible to predict the properties of any of these crystal forms.
[0101] X-ray powder diffraction (XRPD) is a rapid analytical technique mainly used for phase identification of crystalline materials and can provide information about unit cell size. The analyzed material is finely ground, homogenized, and the average volume composition is determined. The X-ray diffractometer generates X-rays in an x-ray tube and directs the X-rays at the sample. As the sample and detector rotate, the intensity of the reflected X-rays is recorded. When the geometry of the incident X-rays that hit the sample satisfies the Bragg equation, constructive interference occurs and intensity peaks appear. The detector records and processes this X-ray signal and converts the signal into a count rate, which is then output to a device (such as a printer or computer display). The geometry of the X-ray diffractometer is such that the sample is rotated at an angle θ on the path of the collimated X-ray beam while the X-ray detector is mounted on an arm to collect the diffracted X-rays and those that rotate at an angle of 2θ. The collected data is used to generate an X-ray powder diffraction pattern.
[0102] As used herein, the term "X-ray powder diffraction pattern" refers to a plot of intensity on the y-axis versus angle 2θ of the detector on the x-axis. X-ray powder diffraction pattern peak positions are generally reported for polymorphs in terms of angular position (2θ) with a tolerance of ±0.1 as specified by the US Pharmacopeia, pages 1843 to 1844 (1995).
[0103] When comparing two powder X-ray diffraction patterns, it is intended to use a variability of ±0.1. In practice, if a diffraction pattern peak from one pattern is assigned a range of angular positions (2θ) that is ±0.1 of the measured peak position, and a diffraction pattern peak from the other pattern is assigned a range of angular positions (2θ) that is ±0.1 of the measured peak position, and if these ranges of peak positions overlap each other, then the two peaks are considered to have the same angular position (2θ).
[0104] Those skilled in the art will appreciate that a given polymorph analyzed by different instruments, experiments, at different temperatures, etc., may produce spectra with a certain amount of variation. However, the curves and ratios of spectra for the same polymorph will be identifiable. Therefore, a shift or drift of the spectrum will generally not prevent one skilled in the art from actively identifying the presence of a given polymorph. Therefore, in one embodiment, the X-ray diffraction pattern is shifted along the X-axis by up to and including 10%, e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10%.
[0105] Drift is a measurement error caused by a gradual shift in the instrument's measured value over time. Although drift can be accelerated by improper operation, all measuring instruments will experience drift during their lifetime.
[0106] In one embodiment, the farostat polymorphs disclosed herein are prepared using the following manufacturing method (also described in Figure 1A ) produces:
[0107]
[0108] preparation
[0109] A DHODH inhibitor is a moiety (such as a compound) that inhibits (eg, reduces or blocks) the activity of a DHODH enzyme (see Background Art for a definition thereof).
[0110] In one embodiment, the DHODH inhibitor is provided as a pharmaceutical formulation.
[0111] The pharmaceutical compositions of the present disclosure can be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intraventricular, transdermal, percutaneous (e.g., WO98 / 20734), subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, intravaginal, or rectal.
[0112] In one embodiment, the pharmaceutical formulation is for oral administration, for example, formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries and suspensions for ingestion by the patient.
[0113] Excipients may include lactose, dextrin, glucose, sucrose, sorbitol, starches, sugars, sugar alcohols and cellulose.
[0114] Other suitable forms for administration include parenteral administration, for example, injection or infusion, such as bolus injection or continuous infusion.
[0115] In the case where the product is used for injection or infusion, it can be in the form of a suspension, solution or emulsion in an oily or aqueous vehicle and it can contain a dispensing agent, such as a suspending agent, a preservative, a stabilizer and / or a dispersant. Alternatively, the molecule can be in an anhydrous form for reconstitution with a suitable sterile liquid before use. The pharmaceutically acceptable carrier in the therapeutic composition may additionally contain a liquid, such as water, saline, glycerol and ethanol. In addition, auxiliary substances (such as wetting agents, emulsifiers, lubricants or pH buffer substances) may be present in these compositions. A detailed discussion of pharmaceutically acceptable carriers is available in Remington's Pharmaceutical Sciences (Mack Publishing Company, NJ 1991).
[0116] treat
[0117] As used herein, treatment refers to situations where a patient has a disease or condition, such as an autoimmune disease (particularly those disclosed herein), and an agent according to the present disclosure is administered to stabilize the disease, delay the disease, ameliorate the disease, cause the disease to remit, maintain disease remission, or cure the disease. As used herein, treatment includes administering an agent according to the present disclosure for treatment or prevention.
[0118] Treatment or therapy may be used preventively.
[0119] As used herein, a therapeutically effective amount is an amount within a range that produces the desired physiological effect while minimizing side effects.
[0120] As used herein, disease-modifying therapy refers to therapy that allows the immune system to reset and rebalance itself so that it functions more normally following treatment.
[0121] The DHODH inhibitors of the present disclosure or formulations comprising the same can be administered in a dosage range of 1 mg to 400 mg / day, such as 10 mg to 400 mg / day, 50 mg to 400 mg / day, 100 mg to 400 mg / day, 150 mg to 400 mg / day, 200 mg to 400 mg / day, 250 mg to 400 mg / day, 300 mg to 400 mg / day or 350 mg to 400 mg / day.
[0122] In particular, a dosage in the range of 100 mg to 400 mg / day is used. Thus, a daily dosage may be, for example, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 110 mg, 120 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 210 mg, 220 mg, 230 mg, 240 mg, 250 mg, 260 mg, 270 mg, 280 mg, 290 mg, 300 mg, 310 mg, 320 mg, 330 mg, 340 mg, 350 mg, 360 mg, 370 mg, 380 mg, 390 mg or 400 mg.
[0123] In one embodiment, the treatment is administered daily (e.g., once a day or twice a day). In one embodiment, the treatment is administered once a day.
[0124] In one embodiment, farostat is administered orally (eg, as a tablet or capsule or cachet).
[0125] As used herein, a co-morbidity refers to a situation in which a patient suffers from a secondary or underlying health condition.
[0126] As used herein, combination therapy (including additional therapy) is one in which two or more treatment regimens are employed, particularly simultaneously. The treatments may be separate formulations or co-formulated. They may be administered simultaneously or at different times. However, the pharmacological effects of the treatments will coexist in the patient.
[0127] As used herein, additional therapy refers to therapy other than a DHODH inhibitor. This additional therapy may be an anti-inflammatory agent, including but not limited to non-steroidal anti-inflammatory agents (NSAIDs), disease-modifying anti-rheumatic drugs (DMARDs), statins (including HMG-CoA reductase inhibitors such as simvastatin), biologics (biologics), steroids, immunosuppressants, salicylates, and / or microbicides.
[0128] Nonsteroidal anti-inflammatory agents include antimetabolites (such as methotrexate) and anti-inflammatory gold agents (including sodium aurothiobutyrate, gold thiomalate or gold salts such as auranofin). Biological agents include anti-TNF agents (including adalimumab, etanercept, infliximab, anti-IL-1 agents, anti-IL-6 agents, anti-CD20 agents, anti-B cell agents (such as rituximab), anti-T cell agents (anti-CD4 antibodies), anti-IL-15 agents, anti-CLTA4 agents, anti-RAGE agents), antibodies, soluble receptors, receptor binding proteins, cytokine binding proteins, mutant proteins with altered or attenuated functions, RNAi, polynucleotide aptamers, antisense oligonucleotides or ω3 fatty acids. Steroids including cortisone, prednisolone, or dexamethasone (also called corticosteroids) may also be used in combination therapy.
[0129] Immunosuppressants used in combination therapy according to the present disclosure include cyclosporin, FK506, rapamycin, mycophenolic acid. Salicylates used in the combination therapy include aspirin, sodium salicylate, choline salicylate and magnesium salicylate. Microbicides include quinine and chloroquine.
[0130] As used herein, anti-inflammatory agents refer to moieties that reduce inflammation, such as nonsteroidal anti-inflammatory agents, steroids, and the like.
[0131] In one embodiment, the combination therapy comprises an anti-CD20 agent or a biosimilar thereof, such as rituximab (Rituxan / rituximab), rituximab biosimilar, Gazyva, Kesimpta, Ocrevus / ocrelizumab, Ruxience, Truxima, Zevalin, Arzerra, AcellBia, HLX01, Reditux, Ritucad, or Zytux.
[0132] In one embodiment, the combination therapy comprises a treatment independently selected from the group consisting of corticosteroids (e.g., oral prednisone and intravenous methylprednisolone), plasma exchange (plasmapheresis), interferon beta agents, glatiramer acetate, fingolimod, dimethyl fumarate, diroximel fumarate, teriflunomide, siponimod, cladribine, aurelizumab, natalizumab, and alemtuzumab.
[0133] In one embodiment, the combination therapy comprises a therapy that alleviates or reduces symptoms of multiple sclerosis, for example, a muscle relaxant (such as baclofen, tizanidine, and cyclobenzaprine), an agent that reduces fatigue (such as amantadine, modafinil, methylphenidate), or an agent that increases walking speed (such as dalfampridine).
[0134] In one embodiment, the combination therapy comprises cannabis or a derivative thereof, for example, cannabis oil.
[0135] In one embodiment, the combination therapy comprises a second DHODH inhibitor. In one embodiment, the additional therapy comprises teriflunomide. In one embodiment, the additional therapy comprises vidofludimus. In one embodiment, the combination therapy does not comprise a second DHODH inhibitor. In an embodiment, the combination therapy does not comprise teriflunomide and / or vidofludimus.
[0136] In one embodiment, the combination therapy comprises a disease-modifying therapy, e.g., selected from the group consisting of alemtuzumab, avonex, interferon beta, cladribine, daclizumab, dimethyl fumarate, extavia, fingolimod, glatiramer acetate, natalizumab, ocrelizumab, plegridy, rebif, siponimod, and a combination of two or more thereof.
[0137] In one embodiment, the additional therapy comprises interferon beta (IFN-β), such as interferon beta-1a or interferon beta-1b. Thus, in one embodiment, the additional therapy comprises interferon beta-1a. In an alternative embodiment, the additional therapy comprises interferon beta-1b.
[0138] In one embodiment, the combination therapy comprises a Bruton's tyrosine kinase (BTK) inhibitor, e.g., Ibrutinib, Acalabrutinib, Zanubrutinib, Evobrutinib, ABBV-105, Fenebrutinib, GS-4059, Spebrutinib, and / or HM71224.
[0139] In one embodiment, the additional therapy comprises glatiramer acetate. In one embodiment, the additional therapy comprises natalizumab. In one embodiment, the additional therapy comprises mitoxantrone. In one embodiment, the additional therapy comprises fingolimod. In one embodiment, the additional therapy comprises siponimod. In one embodiment, the additional therapy comprises dimethyl fumarate. In one embodiment, the additional therapy comprises alemtuzumab. In one embodiment, the additional therapy comprises cyclophosphamide. In one embodiment, the additional therapy comprises cladribine. In one embodiment, the additional therapy comprises aurelizumab. In one embodiment, the additional therapy comprises dimethyl fumarate. In one embodiment, the additional therapy comprises daclizumab. In one embodiment, the additional therapy comprises azathioprine. In one embodiment, the additional therapy comprises methotrexate. In one embodiment, the additional therapy does not comprise methotrexate. In one embodiment, the additional therapy comprises lacquinimod.
[0140] Autoimmune diseases
[0141] As used herein, autoimmune disease refers to any disease or condition in which an individual's immune system mistakenly targets the individual's own normal "healthy" cells, and is particularly characterized by abnormal T cell and / or B cell activation.
[0142] As used herein, aberrant T cell and / or B cell activation refers to abnormal T cell and / or B cell activation, particularly wherein the abnormal cells recognize self or self antigens.
[0143] Severe autoimmune disease is one in which the disease is not controlled by standard of care medications / treatments. A flare is a period of worsening of the disease.
[0144] As used herein, "inadequate control" refers to where standard of care medications fail to alleviate or control symptoms, particularly where the patient's quality of life is adversely affected.
[0145] As used herein, a "defined endpoint" refers to a clinically defined point, such as remission or stable disease.
[0146] In one embodiment, in maintenance therapy, for example, farostat is used at low doses. As used herein, maintenance therapy refers to continuous treatment to stabilize the disease or maintain disease remission, for example, wherein the dose administered is low and particularly frequent. For example, a dose of 100 to 200 mg provided once or twice a day can be used as maintenance therapy.
[0147] In one embodiment, the autoimmune disease is an autoimmune skin disease, i.e., an autoimmune disease that manifests or presents in the skin, particularly the dermis and / or epidermis, such as lupus. In one embodiment, the autoimmune skin disease is selected from the group comprising: vitiligo, alopecia, Behcet's disease, dermatitis herpetiformis, dermatomyositis, lichen planus, linear IgA disease, cutaneous lupus, morphea / scleroderma, ocular cicatricial pemphigoid, pemphigoid (such as bullous pemphigoid or gestational pemphigoid), pemphigus (such as pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, IgA pemphigus, vegetative pemphigus or paraneoplastic pemphigus), vasculitis, epidermolysis bullosa acquired, psoriasis, bullous dermatosis and atopic dermatitis.
[0148] In one embodiment, the autoimmune skin disease is selected from the group comprising vitiligo and alopecia. In one embodiment, the autoimmune skin disease is vitiligo and alopecia.
[0149] In one embodiment, the autoimmune skin disease is vitiligo. In one embodiment, the autoimmune skin disease is vitiligo selected from the group comprising segmental vitiligo or non-segmental vitiligo. In one embodiment, the vitiligo is segmental vitiligo. In one embodiment, the vitiligo is non-segmental vitiligo (e.g., focal vitiligo, systemic vitiligo, or acrofacial vitiligo).
[0150] In one embodiment, the autoimmune skin disease is alopecia. In one embodiment, the alopecia is selected from the group comprising diffuse alopecia areata, alopecia areata in a single location, alopecia areata creeping, alopecia areata barbae, alopecia totalis, or alopecia universalis. In one embodiment, the alopecia is diffuse alopecia areata. In one embodiment, the alopecia is alopecia areata in a single location. In one embodiment, the alopecia is alopecia areata creeping. In one embodiment, the alopecia is alopecia areata barbae. In one embodiment, the alopecia is alopecia totalis. In one embodiment, the alopecia is alopecia universalis.
[0151] Thus, in one embodiment, the autoimmune disease is selected from the group comprising or consisting of acute disseminated encephalomyelitis (adem), acute necrotizing hemorrhagic leukoencephalitis, Addison's disease, adrenal insufficiency, hypocortisolism, amyloidosis, ankylosing spondylitis, spondyloarthritis, Strumpell-Marie disease, disease), anti-GBM / anti-TBM nephritis, antiphospholipid syndrome (aps), autoimmune angioedema, autoimmune aplastic anemia, autoimmune dysautonomia, autoimmune hepatitis, autoimmune hyperlipidemia, autoimmune immunodeficiency, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), Canale-Smith syndrome, autoimmune myocarditis, autoimmune oophoritis, autoimmune pancreatitis (AIP), autoimmune polyglandular syndrome (types I, II, and III), autoimmune retinopathy (AR), autoimmune thrombocytopenic purpura (ATP), autoimmune thyroid disease, autoimmune urticaria, axonal / neuronal neuropathy, balo disease, behcet's disease, bullous pemphigoid, cardiomyopathy, Castleman disease, celiac disease, chagas disease disease), chronic inflammatory demyelinating polyneuropathy (CIDP), chronic relapsing multifocal osteomyelitis (CRMO), Churg–Strauss syndrome, cicatricial pemphigoid / benign mucous membrane pemphigoid (CP), Crohn's disease, inflammatory bowel disease, colitis (including ulcerative colitis), enteritis, ileitis, Cogans syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, crest disease, cryoglobulinemia, demyelinating neuropathy, dermatitis herpetiformis, Duhring's diseasedisease), dermatomyositis, type I diabetes, discoid lupus erythematosus (DLE), Dressler's syndrome, endometriosis, epidermolysis bullosa (EB) and epidermolysis acquisita (EBA), eosinophilic gastroenteritis, esophagitis, eosinophilic fasciitis, Schulman's syndrome, erythema nodosum, experimental allergic encephalomyelitis, Evans syndrome, fibrosing alveolitis, giant cell arteritis (temporal arteritis) ), giant cell myocarditis, glomerulonephritis (nonproliferative: focal segmental glomerulosclerosis and membranous glomerulonephritis. Proliferative: IgA nephropathy), Goodpasture's syndrome, granulomatosis with polyangiitis (GPA) (formerly Wegener's granulomatosis), Graves' disease, Guillain-Barré syndrome, Miller Fisher's Fisher syndrome, acute motor axonal neuropathy, acute motor sensory axonal neuropathy, acute panautonomic neuropathy, Bickerstaff's brainstem encephalitis, Hashimoto's encephalitis, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura, herpes gestationis, hypogammaglobulinemia, idiopathic pulmonary fibrosis, idiopathic thrombocytopenic purpura (ITP), IgA nephropathy (IGAN), Berger's syndrome, synpharyngitic glomerulonephritis (synpharyngitic glomerulonephritis), IgA pemphigus, IgG4-related sclerosing disease, immunomodulatory infertility, inclusion body myositis, insulin-dependent diabetes mellitus, interstitial cystitis, Isaac's syndrome, neuromyotonia, juvenile arthritis, juvenile myositis, Kawasaki syndrome, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, woody conjunctivitis, linear IgA dermatosis (LAD), pemphigoid, systemic lupus erythematosus (SLE), Lyme disease, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), monoclonal gammopathy (monoclonalgammaopathy), Mooren's ulcer, Mucha-Habermann disease, multiple sclerosis, myasthenia gravis, myositis, narcolepsy, neuromyelitis optica (devic's), neuromyotonia, Isaac syndrome (acquired, tumor-associated, hereditary), neutropenia, ocular cicatricial pemphigoid, optic neuritis, oophoritis, opsoclonus-myoclonus syndrome, orchitis, relapsing rheumatic disease, pandas (pediatric autoimmune neuropsychiatric disorder associated with streptococci), tumor-associated Autoimmune multi-organ syndrome (PAMS), tumor-associated cerebellar degeneration, paraneoplastic pemphigus (PNP), paroxysmal nocturnal hemoglobinuria (PNH), ParryRomberg syndrome, Parsonnage-Turner syndrome, pars planitis (peripheral uveitis), pemphigoid gestationis (PG), pemphigus vulgaris (PV), pemphigus foliaceus (PF), peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia, Poems syndrome, polyarteritis nodosa (PAN), polymyalgia rheumatica, polymyalgia Myositis, post-myocardial infarction syndrome, postpericardiotomy syndrome, progesterone dermatitis, primary biliary cirrhosis, Hanot's syndrome, primary sclerosing cholangitis (PSC), sclerosing cholangitis, psoriasis, psoriatic arthritis, pyoderma gangrenosum, pure red cell aplasia, Rasmussen's encephalitis, chronic focal encephalitis (CFE), Raynaud's phenomenon, reactive arthritis, Reiter's syndrome, restorerin-associated retinopathy (RAR), reflex sympathetic dystrophy, Reiter's syndrome, Relapsing polychondritis, restless legs syndrome, retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt's syndrome, scleritis, scleroderma, systemic sclerosis, Sjogren's syndrome, sperm and testicular autoimmunity, stiff-man syndrome, subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia, Takayasu's arteritis, temporal arteritis / giant cell arteritis, thromboangiitis obliterans, Buerger's disease, thrombocytopenic purpura (TTP), Tolosa-Hunt syndrome, transverse myelitis, undifferentiated connective tissue disease (UCTD), uveitis, Takayasu's arteritis, temporal arteritis, Buerger's disease, cutaneous vasculitis, Kawasaki disease, polyarteritis nodosa, Behcet's syndrome, Schüll-Strauss syndrome, cutaneous vasculitis, Henoch-Schüll purpura, microscopic polyangiitis, Wegener's granulomatosis, Golfer's vasculitis, bullous dermatosis, and Wegener's granulomatosis (now called granulomatosis with polyangiitis (GPA)).
[0152] In one embodiment, the autoimmune disease is selected from the group comprising or consisting of: ANCA vasculitis, IgA nephropathy (Berger's), pemphigus vulgaris / bullous pemphigoid, ITP, primary biliary cirrhosis, autoimmune thyroiditis (Grave's disease), Hashimoto's disease, lupus nephritis, membranous glomerulonephritis (or membranous nephropathy), APS, myasthenia gravis, neuromyelitis optica, primary Sjögren's syndrome (primary ), autoimmune neutropenia, autoimmune pancreatitis, dermatomyositis, autoimmune uveitis, autoimmune retinopathy, Behcet's disease, IPF, systemic sclerosis, liver fibrosis, autoimmune hepatitis, primary sclerosing cholangitis, Goodpasture's syndrome, pulmonary alveolar proteinosis, chronic autoimmune urticaria, psoriasis, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis (axial spodyloarthritis), transplantation (including GvHD), asthma, COPD, giant cell arteritis, refractory autoimmune cytopenia, Evan's syndrome (autoimmune hemolytic anemia), type I diabetes, sarcoidosis, polymyositis, ulcerative colitis, Crohn's disease, celiac disease, Waldenstrom's macroglobulinemia, focal segmental glomerulosclerosis, chronic Lyme disease (Lyme borreliosis), lichen planus, stiff-person syndrome, dilated cardiomyopathy, autoimmune (lymphocytic) oophoritis, acquired epidermolysis bullosa, autoimmune atrophic gastritis, pernicious anemia, atopic dermatitis, atherosclerosis, multiple sclerosis, Rasmussen's encephalitis, Guillain-Barré syndrome, acquired neuromyotonia, and stroke.
[0153] In one embodiment, the autoimmune disease is selected from the group comprising or consisting of: hidradenitis suppurativa, scleroderma (systemic scleritis), lichen planus, morphea, psoriasis, type 1 diabetes, autoimmune thyroiditis, Graves' disease, endometriosis, celiac disease, Crohn's disease, ulcerative colitis, axial spondylitis, juvenile arthritis, relapsing rheumatic disease, psoriatic arthritis, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus (SLE), undifferentiated connective tissue disease (UCTD), multiple sclerosis type II, restless legs syndrome, optic neuritis, uveitis, scleritis, Moren's ulcer, Ménière's disease, Graves' ophthalmopathy, neuromyelitis optica, Susac's syndrome, and lupus erythematosus.
[0154] As used herein, an autoimmune skin disease or disorder refers to any disease or condition in which the individual's immune system (e.g., individual T cells and / or B cells) mistakenly targets individual skin tissue or cells (including hair follicles). Faroxetine can block the biosynthesis of pyrimidines, which is believed to cause cell cycle arrest, leading to pro-inflammatory cytokine production and / or T cell and / or B cell apoptosis reduction. Therefore, it is believed that Faroxetine has the potential to treat various autoimmune skin diseases (such as vitiligo and alopecia).
[0155] As used herein, vitiligo refers to an autoimmune skin disease characterized by loss of skin pigmentation patches. Vitiligo occurs when melanocytes die or cease to function. This results in a loss of melanin, which is responsible for skin pigmentation. Pale areas of the skin are more susceptible to sunburn, making it important for vitiligo patients to take appropriate precautions. The condition can affect the skin of any part of the body, but is more commonly seen on the face, neck, hands, and skin folds. Vitiligo can also affect the hair or inside of the mouth.
[0156] There are 2 types of vitiligo - non-segmental and segmental. Non-segmental vitiligo is significantly more common than segmental, with about 90% of patients suffering from this form of the disease. Patients with non-segmental vitiligo usually have symptoms on both sides of the body, i.e., the white patches tend to appear as symmetrical patches. In contrast, segmental vitiligo usually presents as white patches in only one area of the body.
[0157] There is currently no available treatment that can stop the progression of vitiligo. Therefore, the white patches caused by vitiligo are usually permanent. Therefore, available treatments (such as steroid creams, light therapy, or camouflage creams) focus on reducing the appearance of the white patches.
[0158] As used herein, alopecia areata, baldness or spot baldness refers to an autoimmune skin disease in which hair follicles are targeted by the immune system. This results in inhibition of hair growth and hair loss. Hair loss usually appears in clumps and may grow back, although the hair may fall out again. Alopecia can be further subdivided into:
[0159] Diffuse alopecia areata, in which hair loss is widespread throughout the scalp;
[0160] ●Monochromic alopecia areata, in which hair loss is in only one area;
[0161] Multifocal alopecia areata, in which hair loss occurs in multiple areas;
[0162] Alopecia areata, in which there is a sudden thinning of hair as opposed to hair loss in patches
[0163] Alopecia areata, in which hair loss is limited to the beard;
[0164] Alopecia totalis, in which there is complete hair loss on the scalp; and
[0165] ●Alopecia universalis, in which all body hair is lost, including pubic hair.
[0166] There is no known cure for baldness. Treatment options typically include corticosteroids (such as clobetasol or fluocinonide), minoxidil, immunosuppressants (such as cyclosporine), and diphenylcyclopropenone. Wigs or hair tufts can be used to cover bald areas, although some patients may find these uncomfortable to wear.
[0167] Vitiligo and alopecia areata are not life-threatening and are not contagious. However, the symptoms of both diseases are highly visible and therefore can also have adverse effects on the emotional and psychological health of patients suffering from either or both diseases.
[0168] In this regard, studies have shown that vitiligo and alopecia tend to occur together more often in patients than by chance. In addition, both diseases are characterized by a plaque distribution and are minimally symptomatic compared to other more inflammatory skin conditions such as atopic dermatitis or psoriasis. The similarities between the two autoimmune skin diseases extend further beyond common clinical symptoms - they also share common pathogenesis similarities. For example, it is believed that increased reactive oxygen species (ROS) and high cellular stress levels activate the innate immune system that triggers both conditions. In addition, studies in mouse models have suggested that IFN-γ-driven immune responses and cytotoxic CD8+T cells are the main pathogenic factors in both diseases. See, review by Rork et al., Curr Opin Pediatr 2016Aug; 28(4): 463-469. Given the involvement of the IFN-γ signaling pathway in both diseases, clinical trials of ruxolitinib, an inhibitor targeting JAK, a downstream effector of IFN-γ signaling, are currently underway for both vitiligo and alopecia.
[0169] Therefore, while not wishing to be bound by theory, the inventors believe that farostat has the potential to treat both vitiligo and alopecia by virtue of the various similarities between the two diseases, particularly the key role of cytotoxic CD8+ T cells in both diseases.
[0170] In one embodiment, the autoimmune disease is selected from the group comprising or consisting of lichen planus, hidradenitis suppurativa, celiac disease, ulcerative colitis, Crohn's disease, Graves' disease, autoimmune thyroiditis, endometriosis, multiple sclerosis, and optic neuritis.
[0171] Multiple sclerosis (MS) is a disease in which the myelin sheath that insulates nerve cells in the brain and spinal cord is damaged. As a result of this damage, the ability of the nervous system to transmit signals correctly is destroyed. This in turn causes a range of serious physical and mental problems, such as double vision, monocular blindness, muscle weakness, sensory or coordination problems, language problems, acute or chronic pain, bladder and bowel difficulties, depression and mood swings.
[0172] The condition begins in most cases as a clinically isolated syndrome over many days, with most suffering from motor or sensory problems. The course of symptoms initially occurs in two patterns, which is a sudden exacerbation episode lasting a few days to months, called a relapse, followed by improvement in most cases, or gradual worsening over time without a recovery period. Relapses are generally unpredictable and occur without warning.
[0173] The cause of multiple sclerosis is currently unknown, although the underlying mechanism is thought to be the destruction of the myelin sheath by the individual's own immune system, i.e. multiple sclerosis is considered to be at least partly an autoimmune disease. It is the most common immune-mediated disorder affecting the central nervous system, with approximately 2.3 million people infected worldwide. However, there are still many autoimmune diseases that have a serious and negative impact on the lives of many patients.
[0174] In one embodiment, the autoimmune disease is multiple sclerosis (MS). Multiple sclerosis is generally further divided into one of four variants: clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). Therefore, in one embodiment, the autoimmune disease is selected from the group comprising CIS, RRMS, PPMS and SPMS.
[0175] Relapsing-remitting MS (RRMS) is characterized by unpredictable relapses followed by periods of relative quiet (remission) with no new signs of disease activity for months to years. The condition is typically characterized by progressive, ongoing demyelination and associated axonal loss. In one embodiment, the autoimmune disease is RRMS.
[0176] An attack (also called a relapse or exacerbation (also referred to herein as an flare)) is followed by a period of partial or complete recovery (remission). During remission, all symptoms may disappear, or some symptoms may continue and become permanent. However, there is no apparent progression of the disease during remission. RRMS can be further characterized as active (evidence of relapse and / or new MRI activity over a specified period of time) or inactive, and worsening (confirmed increased disability followed by relapse) or non-worsening.
[0177] The relapsing-remitting subtype usually begins with clinically isolated syndrome (CIS). In CIS, a person has attacks suggestive of demyelination, but does not meet the criteria for multiple sclerosis. 30 to 70% of people who experience CIS later develop MS. In one embodiment, the autoimmune disease is CIS.
[0178] Primary progressive MS (PPMS) occurs in about 10 to 20% of individuals without remission after initial symptoms. It is characterized by a progression of disability with spontaneous onset, with no or only occasional and mild remissions and improvements. In one embodiment, the autoimmune disease is PPMS.
[0179] Secondary progressive MS (SPMS) occurs in about 65% of patients with initial relapsing-remitting MS, who eventually have progressive neurological decline between acute attacks without any clear remission periods. Occasional relapses and minor remissions may occur. SPMS can be further characterized as active (evidence of relapses and / or new MRI activity during a specified time period) or inactive, and with progression (evidence of accumulated disability over time, with or without relapses or new MRI activity) or no progression. In one embodiment, the autoimmune disease is SPMS.
[0180] In one embodiment, the disease is chronic inflammatory demyelinating polyneuropathy. In one embodiment, the disease is transverse myelitis. In one embodiment, the disease is neuromyelitis optica.
[0181] In one embodiment, the autoimmune disease is one or more of the following: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis, sarcoidosis, polyarticular juvenile idiopathic arthritis, inflammatory bowel disease (such as ulcerative colitis and Crohn's disease), Reiter's syndrome, fibromyalgia and type 1 diabetes. In one embodiment, the autoimmune disease is not any of them.
[0182] In one embodiment, the autoimmune disease is psoriatic arthritis. In one embodiment, it is not psoriatic arthritis. In one embodiment, the autoimmune disease is ankylosing spondylitis. In one embodiment, it is not ankylosing spondylitis. In one embodiment, the autoimmune disease is multiple sclerosis. In one embodiment, it is not multiple sclerosis. In one embodiment, the autoimmune disease is Wegener's granulomatosis. In one embodiment, it is not Wegener's granulomatosis. In one embodiment, the autoimmune disease is systemic lupus erythematosus. In one embodiment, it is not systemic lupus erythematosus. In one embodiment, the autoimmune disease is psoriasis. In one embodiment, it is not psoriasis. In one embodiment, the autoimmune disease is sarcoidosis. In one embodiment, it is not sarcoidosis. In one embodiment, the autoimmune disease is polyarticular juvenile idiopathic arthritis. In one embodiment, it is not polyarticular juvenile idiopathic arthritis. In one embodiment, the autoimmune disease is inflammatory bowel disease (such as ulcerative colitis or Crohn's disease). In one embodiment, it is not inflammatory bowel disease (such as ulcerative colitis or Crohn's disease). In one embodiment, the autoimmune disease is Reiter's syndrome. In one embodiment, it is not Reiter's syndrome. In one embodiment, the autoimmune disease is fibromyalgia. In one embodiment, it is not fibromyalgia. In one embodiment, the autoimmune disease is type 1 diabetes. In one embodiment, it is not type 1 diabetes. In one embodiment, the autoimmune disease is arthritis, such as rheumatoid arthritis. In one embodiment, it is not arthritis, such as rheumatoid arthritis.
[0183] In one embodiment, the autoimmune skin disease is not atopic dermatitis. In one embodiment, the autoimmune skin disease is not erythema. In one embodiment, the autoimmune skin disease is not scleroderma. In one embodiment, the autoimmune skin disease is not lupus. In one embodiment, the autoimmune skin disease is not Behcet's disease. In one embodiment, the autoimmune skin disease is not bullous pemphigoid. In one embodiment, the autoimmune skin disease is not IgA pemphigus. In one embodiment, the autoimmune skin disease is not pemphigoid. In one embodiment, the autoimmune skin disease is not ocular cicatricial pemphigoid. In one embodiment, the autoimmune skin disease is not gestational pemphigoid (PG), pemphigus vulgaris (PV) or pemphigus foliaceus (PF). In one embodiment, the autoimmune skin disease is not bullous skin disease. In one embodiment, the autoimmune skin disease is not dermatomyositis. In one embodiment, the autoimmune skin disease is not lichen planus. In one embodiment, the autoimmune skin disease is not dermatitis herpetiformis. In one embodiment, the autoimmune skin disease is not bullous skin disease. In one embodiment, the autoimmune skin disease is not a linear IgA skin disease. In one embodiment, the autoimmune skin disease is not a vasculitis.
[0184] Viral infection
[0185] As used herein, virus refers to a virus that causes a viral infection or a viral disease. Therefore, in the context of the present disclosure, virus generally refers to a pathogenic virus. It is not intended to refer to a viral vector or a virus used as a therapeutic agent.
[0186] As used interchangeably herein, viral infection or viral disease refers to an infection or disease caused by the presence of a virus in the body.
[0187] In one embodiment, the virus causing the viral infection is an RNA virus.
[0188] RNA viruses are generally classified as riboviruses (Riboviria) and orthoriboviruses (Orthornavirae). There are single-stranded forms of RNA viruses and double-stranded forms (Group III in the Baltimore classification). Single-stranded viruses are divided into: positive-sense single-stranded RNA viruses (Group IV in the Baltimore classification), negative-sense single-stranded RNA viruses (Group V in the Baltimore classification) and single-stranded RNA viruses with DNA intermediates (Group VI in the Baltimore classification). Therefore, in one embodiment, the virus is a single-stranded RNA virus, for example, a positive-sense single-stranded RNA virus or a negative-sense single-stranded RNA virus.
[0189] In one embodiment, the virus causing the viral infection is Sarbecovirus. Sarbecovirus is a subgenus of viruses that cause severe acute respiratory syndrome. Examples of Sarbecovirus include SARS-CoV, SARS-CoV2, bat SARS coronavirus WIV1, and bat coronavirus RaTG13. The genus is betacoronavirus and the family is coronaviridae. Therefore, in one embodiment, the virus belongs to the coronaviridae.
[0190] Merbecovirus is a subgenus of the virus that causes Middle East respiratory syndrome-related coronavirus. The genus is betacoronavirus and the family is Coronaviridae. Therefore, in one embodiment, the virus is Merbecovirus.
[0191] The present disclosure also extends to treating Embecovirus (referred to as group 2a coronavirus), such as human coronavirus HKU1. Thus, in one embodiment, the virus is Embecovirus. The present disclosure also encompasses Nobecovirus (referred to as group 2d coronavirus).
[0192] In one embodiment, the virus causing the viral infection is SARS-CoV. SARS-CoV is also known as SARS-CoV1 or SARS. In one embodiment, the virus is SARS-CoV2. SARS-CoV2 is also known as coronavirus or COVID-19.
[0193] In one embodiment, the virus is MERS-CoV. MERS-CoV is also known as Middle East Respiratory Syndrome Coronavirus.
[0194] The viral infection may be a mosquito-borne viral disease or due to a mosquito-borne virus. Common examples of mosquito-borne diseases include malaria, chikungunya, dengue, Zika, West Nile virus, and yellow fever. Yellow fever, dengue, and chikungunya are primarily spread by Aedes aegypti mosquitoes. Other mosquito-borne diseases such as epidemic polyarthritis, Rift Valley fever, Ross River fever, St. Louis encephalitis, West Nile fever, Japanese encephalitis, and La Crosse encephalitis are usually carried by several different mosquitoes.
[0195] Thus, in one embodiment, the viral infection is a mosquito-borne viral disease. In other words, in one embodiment, the virus is transmitted by mosquitoes.
[0196] In one embodiment, the virus is a Flavivirus. Flavivirus is a genus of viruses that includes West Nile virus, dengue virus, tick-borne encephalitis virus, yellow fever virus, Zika virus, etc. Flaviviridae is a family. Therefore, in one embodiment, the virus belongs to the Flaviviridae family.
[0197] The present disclosure extends to treating dengue virus. There are 5 serotypes of the virus, all of which can cause a broad spectrum of disease. In one embodiment, the dengue virus is any one of serotypes 1 to 5, in particular serotypes 1, 2, 3 or 4. Thus, in one embodiment, the virus is dengue serotype 1, 2, 3 or 4. In one embodiment, the virus is dengue serotype 1. In one embodiment, the virus is dengue serotype 2. In one embodiment, the virus is dengue serotype 3. In one embodiment, the virus is dengue serotype 4. In one embodiment, the virus is dengue serotype 5.
[0198] In one embodiment, the virus is an alphavirus. Alphavirus is the only genus of the Togaviridae family. There are 31 alphaviruses, including Chikungunya virus, Bebaru virus, Getah virus, Mayaro virus, O'nyong'nyong virus, Ross River virus, and Semliki forest virus.
[0199] In one embodiment, the virus is selected from the group comprising Sabei virus and mosquito-borne viral diseases.
[0200] In one embodiment, the Sabeivirus is SARS-CoV or SARS-CoV-2, in particular SARS-CoV-2.
[0201] In one embodiment, the mosquito-borne viral disease or viral infection is selected from the group comprising dengue, chikungunya and Zika. In one embodiment, the dengue is dengue serotype 1, 2, 3 or 4. Thus, in one embodiment, the virus is selected from the group comprising SARS-CoV-2, dengue, chikungunya and Zika.
[0202] In the context of this specification, comprising is intended to mean "including".
[0203] The embodiments of the present disclosure may be combined where technically appropriate.
[0204] Embodiments are described herein as comprising certain features / elements. The disclosure also extends to separate embodiments consisting of or consisting essentially of said features / elements.
[0205] Technical references, such as patents and applications, are incorporated herein by reference.
[0206] Any embodiment specifically and explicitly described herein may, alone or in combination with one or more further embodiments, form the basis for a disclaimer.
[0207] The Background Art contains technical information and may serve as a basis for modification.
[0208] The present disclosure will now be described with reference to the following examples, which are illustrative only and should not be construed as limiting the scope of the invention.
[0209] This application claims the priority of SG10202201038X, which is incorporated by reference. This priority document may be used as a basis for correction. BRIEF DESCRIPTION OF THE DRAWINGS
[0210] Figure 1A The synthetic route for producing the farostat dominant stable drug substance (DSP) polymorph is shown.
[0211] Figure 1B Flowchart showing the process used to synthesize polymorphs of farostat.
[0212] Figure 1C Table showing the in-process control steps used during the synthesis of farostat polymorphs.
[0213] Figure 2 Shown is the XRPD pattern of Faroxetine DSP polymorph.
[0214] Figure 3 Details showing the peaks of the XRPD pattern of the Faroxerstat DSP polymorph.
[0215] Figure 4A XRPD results for the antisolvent method from Experiment 1 are shown.
[0216] Figure 4B XRPD results for the antisolvent method from Experiment 2 are shown.
[0217] Figure 5A XRPD results of slurries from experiment 1 are shown (25°C).
[0218] Figure 5B XRPD results of slurry from experiment 2 are shown (25°C).
[0219] Figure 5C XRPD results of slurries from experiment 3 are shown (25°C).
[0220] Figure 5D XRPD results of slurry from experiment 4 are shown (50°C).
[0221] Figure 5E XRPD results of slurry from experiment 5 are shown (50°C).
[0222] Fig. 5F XRPD results of slurry from experiment 6 are shown (50°C).
[0223] Fig. 6A XRPD results for solvent-thermal heating / cooling experiment 1 are shown.
[0224] Figure 6B XRPD results for solvent-thermal heating / cooling experiment 2 are shown.
[0225] Figure 7 XRPD results of evaporation experiments are shown.
[0226] Figure 8 XRPD results of the milling experiments are shown.
[0227] Fig. 9 XRPD results of a recrystallization experiment are shown.
[0228] Fig.10 Shown are the XRPD results of a reactive crystallization experiment.
[0229] Fig.11 Shown are XRPD results of a crystalline form of farostat from evaporation of a THF solution.
[0230] Fig.12 Shown are XRPD results for a crystalline form of farostat from anti-solvent in THF-water.
[0231] Fig.13 XRPD results of a spray-dried farostat sample are shown.
[0232] Fig.14 XRPD results for farostat from a solvent evaporation experiment are shown.
[0233] Fig.15 XRPD results of freeze-dried farostat sample are shown.
[0234] Fig.16 XRPD results of the milled farostat sample are shown.
[0235] Fig.17 TGA and DSG curves of Faroxetine DSP polymorph are shown.
[0236] Fig.18 Shown are the TGA and DSC curves of the crystalline form of farostat from evaporation of THF solution.
[0237] Fig.19 Shown are TGA and DSC curves of a crystalline form of farostat from an anti-solvent in THF-water.
[0238] Fig. 20A Polarized light microscopy (PLM) images of farostat at 200x magnification 27 hours after grinding are shown.
[0239] Fig. 20B PLM images of farostat at 500x magnification are shown 27 hours after grinding.
[0240] Fig.21A PLM images at 200x magnification from recrystallization experiments are shown.
[0241] Fig. 21B PLM images at 500x magnification from recrystallization experiments are shown.
[0242] Fig.22A Shown is a PLM image at 200x magnification from a reactive recrystallization experiment using HCl-NaOH.
[0243] Fig. 22B Shown is a PLM image at 500x magnification from a reactive recrystallization experiment using HCl-NaOH.
[0244] Fig. 22C Shown is a PLM image at 200x magnification from a reactive recrystallization experiment using NaOH-HCl.
[0245] Fig.22D Shown is a PLM image at 500x magnification from a reactive recrystallization experiment using NaOH-HCl.
[0246] Fig.23A PLM image at 200x magnification showing the crystalline form of farostat from evaporation of THF solution.
[0247] Fig. 23B PLM image at 500x magnification showing the crystalline form of farostat from evaporation of THF solution.
[0248] Fig.24A PLM image at 200x magnification of the crystalline form of farostat from anti-solvent in THF-water is shown.
[0249] Fig. 24B PLM image at 500x magnification of the crystalline form of farostat from anti-solvent in THF-water is shown.
[0250] Fig.25AXRPD results from solvent solubility evaluation experiments are shown.
[0251] Fig.25B Summary table showing the results of the solubility evaluation experiments. * = Very little solid available to perform XRPD. Figure 1 = XRPD pattern of Faroxetine DSP polymorph.
[0252] Fig.26 Shown are XRPD results from bead milling of the Faroxerstat DSP polymorph.
[0253] Fig.27A Shown are XRPD results from a solvent drop milling experiment.
[0254] Fig.27B Summary table showing results from solvent drop milling experiments. *WP = white powder, Pattern 1 = XRPD pattern of Faroxetine DSP polymorph.
[0255] Fig.28A XRPD results from thermal cycling experiments are shown.
[0256] Fig.28B Summary table showing results from thermal cycling experiments. WS = wet slurry, CS = clear solution, Pattern 1 = XRPD pattern of the Faroxerstat DSP polymorph.
[0257] Fig.29A XRPD results from room temperature evaporation experiments are shown.
[0258] Fig.29B Summary table showing results from room temperature evaporation experiments. Figure 1 = XRPD pattern of Faroxetine DSP polymorph.
[0259] Fig. 30A Shown are XRPD results from a fast evaporation experiment of 1,3-dioxolane at 50°C.
[0260] Fig. 30B Shown are XRPD results from a fast evaporation experiment of 1,4-dioxane at 50°C.
[0261] Fig. 30C Shown are XRPD results from a fast evaporation experiment of 2-propanol and 1,1-dimethoxymethane at 50°C.
[0262] Fig.30D Shown are XRPD results from a fast evaporation experiment at 50 °C for THP, THF, 2-methyl THF, and 1,1,1,3,3,3-hexafluoro-2-propanol.
[0263] Fig.30E Shown are XRPD results from a fast evaporation experiment of 2-ethoxyethanol at 50°C.
[0264] Fig.30F Shown are XRPD results from a fast evaporation experiment of DMF at 50°C.
[0265] Figure 30G Summary table showing results from fast evaporation experiments at 50° C. WS = wet slurry, ** = little solids, Pattern 1 = XRPD pattern of the Faroxerstat DSP polymorph.
[0266] Fig.31A Shown are XRPD results from a fast evaporation experiment at 100°C with DMA.
[0267] Fig.31B Shown are XRPD results from a fast evaporation experiment of DMF at 100°C.
[0268] Fig.32A Shown are XRPD results from a fast cooling experiment with 1,3-dioxolane.
[0269] Fig.32B Summary table showing results from rapid cooling experiments. Panel 1 = XRPD pattern of Faroxetine DSP polymorph, WS = wet slurry, CS = clear solution.
[0270] Fig.33A XRPD results from a 2 week slurry experiment are shown.
[0271] Fig.33B Shown are XRPD results from a 2 week slurry experiment after flash evaporation at 100°C.
[0272] Fig.33C Summary table showing results from a 2 week slurry experiment.Pattern 1 = XRPD pattern of Faroxetine DSP polymorph, Pattern 1+ = Pattern 1 with additional peaks, WS = wet solid, CS = clear solution.
[0273] Fig.34A XRPD results from antisolvent addition (water) experiments are shown.
[0274] Fig.34B Summary table showing results from anti-solvent addition (water) experiments. Figure 1 = XRPD pattern of Faroxetine DSP polymorph.
[0275] Fig.34C XRPD results from antisolvent addition (acetone) experiments are shown.
[0276] Fig.34D Summary table showing results from anti-solvent addition (acetone) experiments.Pattern 1+ = Pattern 1 + additional peaks.
[0277] Fig.34E Summary table showing results from antisolvent addition (heptane) experiments.
[0278] Fig.34F Summary table showing results from antisolvent addition (MEK) experiments.
[0279] Fig.35 Shown are XRPD results from an antisolvent addition + fast cooling experiment of 1,4-dioxane with MEK as the antisolvent.
[0280] Fig.36A Shown are XRPD results from antisolvent addition experiments at 50°C.
[0281] Fig.36B Summary table showing XRPD results from anti-solvent addition experiments at 50°C. Panel 1 = XRPD pattern of Faroxetine DSP polymorph.
[0282] Fig.37 The XRPD diffraction pattern of the farostat DSP polymorph (CS-276-22 Pattern 1) is shown compared to the XRPD diffraction pattern of the 1,1,1,3,3,3-hexafluoro-2-propanol polymorph before drying (Pattern 2) and after drying (Pattern 1 after drying).
[0283] Fig.38 XRPD peak list showing the polymorph of 1,1,1,3,3,3-hexafluoro-2-propanol (Pattern 2).
[0284] Fig.39A Shown is the Thermogravimetry (TG) / Differential Scanning Calorimetry (DSC) thermogram of HIFP polymorphs before drying (wet).
[0285] Fig.39B TG / DSC thermogram showing the polymorph of 1,1,1,3,3,3-hexafluoro-2-propanol after drying.
[0286] Fig.40A Showing the polymorphs of 1,1,1,3,3,3-hexafluoro-2-propanol before drying (wet) 1 H NMR spectroscopy.
[0287] Fig.40B It shows that the polymorphs of 1,1,1,3,3,3-hexafluoro-2-propanol after drying 1 H NMR spectroscopy.
[0288] Fig.41A Shown is the Fourier transform infrared spectroscopy (FT-IR) spectrum of the polymorphs of 1,1,1,3,3,3-hexafluoro-2-propanol.
[0289] Fig.41B Shown is the Fourier transform infrared spectroscopy (FT-IR) spectrum of the farostat DSP polymorph.
[0290] Fig.42 Shown is the XRPD diffraction pattern of the DSP polymorph of farostat (CS-276-22 pattern 1) compared to the XRPD diffraction patterns of the 1NMP polymorph before drying (NMP pattern 3) and after drying (NMP dried pattern 1).
[0291] Fig.43 XRPD peak list for NMP polymorph (Pattern 3) is shown.
[0292] Fig.44 TG / DSC thermogram showing NMP polymorphs.
[0293] Fig.45 Showing NMP polymorphs 1 H NMR spectroscopy.
[0294] Fig.46 An overview of the identified polymorphs of farostat is shown. DETAILED DESCRIPTION
[0295] Example
[0296] Example 1 - Synthesis of Faroxetine Preferentially Stable Drug (DSP) Polymorph
[0297] The synthetic pathway and flow chart for the manufacturing method of producing the polymorph of farostat DSP are shown in Figure 1A and Figure 1B middle. Figure 1C is a table describing the in-process control steps used during the synthesis of farostat polymorphs.
[0298] Phase 1 Process Description
[0299] A mixture of 2-chloronicotinic acid, 4-bromo-2,6-difluoroaniline and p-toluenesulfonic acid monohydrate in 2-propanol was heated until the reaction was complete (>90% conversion). The mixture was cooled and filtered, and the filter cake was washed. The product was dried under vacuum to give the crude intermediate 1, which was dissolved in water and the pH was adjusted using sodium hydroxide. The resulting slurry was filtered and the filter cake was washed with HCl (aq) and then acetone. The product was dried under vacuum to give intermediate 1 (C 12 H7BrF2N2O2), yield 70 to 80%.
[0300] Phase 2 Process Description
[0301] Intermediate 1 (C 12A mixture of 1,4-dimethoxyphenylboronic acid, ...
[0302] Example 2 - Materials and Methods
[0303] 1. Reagents
[0304] Table 1 - List of reagents used
[0305]
[0306]
[0307] 2. Instruments
[0308] Milli-Q Direct 8 water purification equipment; Sartorius CP 225D Balance; Mettler-Toledo XP6 Balance; Eppendorf Thermomixer Comfort; Bruker D8 Advance X-ray powder diffractometer (XRPD); Nikon LV100 polarized light microscopy (PLM); TA Q2000 differential scanning calorimetry (DSC); TA Q5000IR thermogravimetric analysis (TGA); Crystal 16, AVANTIUM; rotary evaporator R-114; Planetary Momo mill (pulverisette-6); freeze dryer (Free zoon-6)
[0309] 3. Instrument parameters
[0310] X-ray powder diffractometer (XRPD)
[0311] Approximately 5 to 10 mg of sample was run on an XRPD using the following parameters:
[0312] Tube:Cu:K-α Generator: Voltage: 40 kV; Current: 40 mA; Scan range: 4 to 40 degrees; Sample rotation speed: 15 rpm; Scan rate: 10 degrees / min
[0313] Differential Scanning Calorimetry (DSC) and Modulated DSC
[0314] The sample (about 1 mg) was run with heating from 25°C to 280°C at a rate of 10°C / min using a coiled aluminum pan.
[0315] Thermogravimetric analysis (TGA) method
[0316] The sample (2 to 5 mg) was placed in an open aluminum pan and heated from room temperature to 300°C at a rate of 10°C / min.
[0317] Polarized Light Microscopy (PLM)
[0318] The samples were dispersed in silicone oil and observed under crossed polarizers using an objective lens (10X) and physical lenses (20X and 50X). This resulted in an overall magnification of 200X and 500X.
[0319] Example 3 - Characterization of the physicochemical properties of Faroxetine DSP polymorphs
[0320] The farostat DSP polymorph was characterized using X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA) and polarized light microscopy (PLM). It was then subjected to various recrystallizations and analyses to confirm that it was the DSP polymorph.
[0321] Grinding experiment
[0322] 30 mg of DSP polymorph was ground using a mortar and pestle for 15 minutes and then examined by XRPD. During the grinding process, a few drops of THF were added to the sample. If a new form was identified, it was further characterized by DSC and TGA. The XRPD results are shown in Figure 8 middle.
[0323] Recrystallization experiment
[0324] At room temperature, about 3 mg of the farostat raw material was dissolved with acetic acid to produce a clear solution. The sample was heated to 55°C and more material was added until no more material could be dissolved. Afterwards, the sample was filtered and stored at room temperature, and allowed to recrystallize for about 20 hours before being analyzed by XRPD and PLM. If a new form was identified, it was further characterized by DSC and TGA. The XRPD results are shown in Fig. 9 The PLM image is shown in Fig. 20A and Fig. 20B middle.
[0325] Reactive crystallization experiments
[0326] About 100 mg of DSP polymorph was dissolved with a basic solvent (1N NaOH) to produce a clear solution. After the solution was filtered, an acidic solution (1N HCl) was mixed to precipitate the drug substance, which was then isolated and analyzed by XRPD and PLM. If a new form was identified, it was further characterized by DSC and TGA. The XRPD results are shown in Fig.10 The PLM image is shown in FIG. 22A to FIG. 22D middle.
[0327] Preparation of amorphous samples
[0328] ●Spray drying
[0329] About 1.2 g of DSP polymorph was dissolved in THF solvent to obtain a clear solution. The solution was then spray dried to obtain an amorphous solid dispersion. The parameters used for spray drying are shown below:
[0330] Table 2 - Spray Drying Parameters
[0331]
[0332]
[0333] The spray dried samples were analyzed by XRPD and the results are shown in Fig.13 middle.
[0334] Solvent evaporation
[0335] About 260 mg of the farostat raw material was dissolved in THF solvent to produce a clear solution. The solution was then concentrated to dryness using a rotary evaporator at a temperature of about 40°C. The residual solid was analyzed by XRPD. The XRPD results are shown in Fig.14 The PLM results are shown in Fig.23A and Fig. 23B middle.
[0336] Freeze drying
[0337] About 30 mg of the Faroxal raw material was dissolved in DMSO to produce a clear solution, which was then cooled with acetone containing dry ice. Next, water was added to the sample, which was then cooled again. Finally, the frozen solution was freeze-dried, and the remaining solid was then analyzed by XRPD. The XRPD results are shown in Fig.15 middle.
[0338] Grinding experiment
[0339] About 1.2 g of the Faroxetine raw material was placed in a ball mill. The sample was ground for about 24 cycles (including grinding followed by a 30-minute pause). Afterwards, the sample was analyzed by XRPD and PLM. The XRPD results are shown in Fig.16The PLM results are shown in Fig. 20A and Fig. 20B middle.
[0340] Characterization of DSP polymorphs
[0341] Figure 2 XRPD of Faroxetine DSP polymorph is shown.
[0342] Figure 3 show Figure 2 Detailed position of the peak in .
[0343] Fig.17 TGA and DSG curves of DSP polymorphs are shown.
[0344] Example 4 - Approximate Solubility of DSP in Various Solvents and Solvent Mixtures
[0345] Approximate solubility was tested by manual dilution combined with visual observation at room temperature. The solubility of the material in different single solvents and mixed solvents was determined at a concentration at which particles of fafostat were not visually observable in the solvent.
[0346] The results of the solubility study of farostat DSP polymorphs in 43 solvent systems are shown in Table 3 below.
[0347] High solubility (greater than 100 mg / ml) was observed for some solvents. In particular, relatively high solubility of DSP polymorph at room temperature was observed when it was dissolved in THF, 2-MeTHF, THF-MeOH (3: 1), THF-CAN (3: 1), THF-dichloromethane (3: 1), THF-heptane (3: 1), THF-water (3: 1) and THF-MeOH (1: 1).
[0348] In contrast, there were 11 organic solvents / mixed solvents with relatively poor solubility (less than 10 mg / ml).
[0349] Table 3 - Approximate solubility of farostat DSP polymorphs in different solvents
[0350]
[0351] Suspension equilibrium (slurrying) of DSP polymorphs
[0352] Suspensions of DSP polymorphs were prepared in different single and mixed solvents (see Table 4 below). Afterwards, the samples were kept shaking at 25°C and 50°C for 72 hours, after which they were centrifuged at 14,000 rpm for 10 minutes until solid material was separated from the supernatant. The centrifuged samples were studied by XRPD. The samples were dried at 40°C under vacuum overnight and studied by XRPD, DSC and TGA if new XRPD patterns were found. The XRPD results are shown in FIG. 5A to FIG. 5F middle.
[0353] Example 5 - Testing the ability to form DSP polymorphs after processing / treatment
[0354] The farostat DSP polymorph is subjected to processing or treatment to test the physical stability of the form.
[0355] Antisolvent precipitation (antisolvent)
[0356] Based on the solubility results, 50 mg of DSP polymorph was dissolved in the selected solvent (see Table 4) to form a saturated solution. Next, the anti-solvent was slowly added to the solution under stirring until a precipitate formed. If no solid precipitate was present at room temperature, the sample was transferred to a refrigerator and stored at -20°C. Thereafter, the slurry was stirred for 24 hours, after which it was centrifuged at 14,000 rpm for 10 minutes until solid material was separated from the supernatant. The centrifuged samples were studied by XRPD. Next, the sample was dried overnight at 40°C under vacuum conditions. If a crystalline XRPD pattern was found, the sample was further studied by XRPD, DSC, and TGA. The XRPD results are shown in Figure 4A and Figure 3 In B.
[0357] The test parameters are shown in Table 4.
[0358] Table 4 - Screening experiments
[0359]
[0360]
[0361]
[0362] All experiments confirmed that the DSP polymorph was the dominant form. Antisolvents DMSO, NMP, and evaporation of NMP did not produce precipitation.
[0363] Spontaneous precipitation (evaporation) from a saturated solution
[0364] Due to the high solubility of DSP polymorphs in some solvents (see Table 4), these solvents were selected for evaporation experiments. Solutions were prepared according to the solubility of the compound and kept open at room temperature to evaporate the solvent to form crystals. After evaporation was complete, the dried solid was collected and studied by XRPD. If a new XRPD pattern was found, further testing was performed on DSC and TGA. The XRPD results are shown in Figure 7 middle.
[0365] Solvent-heat heating / cooling experiments
[0366] 10 to 30 mg of the original form of ASLAN003 was placed in a glass vial and placed in a thermomixer at 60°C or 50°C. Afterwards, the selected solvent (see Table 4) was slowly added to the sample until the compound was completely dissolved. Next, the sample was transferred to a Crystal 16 crystallizer and cooled to 0°C at a rate of 0.5°C / min, after which it was kept at 0°C for 24 hours. If there was no solid precipitation at 0°C, the sample was transferred to a refrigerator at -20°C.
[0367] Once the cooling process was complete, the sample was centrifuged at 14,000 rpm for 10 minutes until the solid material separated from the supernatant. The wet centrifuged sample was studied by XRPD. Next, the sample was dried at 40 °C overnight under vacuum conditions. If a crystalline XRPD pattern was found, the sample was further studied by XRPD, DSC and TGA. The XRPD results are shown in Fig. 6A and Figure 6B middle.
[0368] Example 6 - Further Characterization of Faroxetine DSP Polymorphs
[0369] Two samples from Example 4 were further characterized and evaluated after drying overnight at 40°C under vacuum:
[0370] 1. THF solvent, by evaporation, and
[0371] 2.THF and water, through an anti-solvent.
[0372] The PLM results are shown in Figures 23 and 24. The XRPD results are shown in Fig.11 and Fig.12 The TGA and DSC results of the samples in the mixed method are shown in Fig.18 and Fig.19 The results of samples in THF solvent by evaporation method and samples in a mixture of THF and water by anti-solvent method confirmed that the polymorph is stable.
[0373] in conclusion
[0374] The experiments showed that the farostat DSP polymorph exhibited good crystallinity and a high melting point with minimal weight loss after heating to 200°C.
[0375] The DSP polymorph of farostat was recrystallized from a variety of solvents in a stable and reproducible manner, indicating that it is a predominantly stable drug polymorph (DSP).
[0376] Example 7 - Particle Size Distribution (PSD) of Faroxetine DSP Polymorph
[0377] Table 5 - PSD results
[0378]
[0379] The data showed that the faroxetine polymorph was the dominant stable drug polymorph.
[0380] Example 8 - Faroxetine polymorph screening experiment
[0381] Solvent solubility screening was performed on the Faroxetine DSP polymorph (also referred to as CS-276-22 in the following examples) to determine its solubility in various solvents and to obtain an initial assessment of the polymorph pattern. An aliquot of the selected solvent (2×50 μL, then 100 μL) was added to a sample of approximately 20 mg of the dominant amorphous Faroxetine until dissolution was observed, or 2 mL was added. The sample was manually agitated and heated to approximately 40° C. in a block attached to a water bath between each aliquot. The clear solution was opened and allowed to evaporate at room temperature. Any solid obtained by slurrying and evaporation was analyzed by X-ray powder diffraction (XRPD).
[0382] exist Fig.25A Displayed in and Fig.25B The results of the solvent solubility evaluation are summarized in . The results show that all solids isolated from 2-propanol, 48% methanol: 52% water (% v / v), 93% ethanol: 7% water (% v / v), 98.5% ethanol: 1.5% water (% v / v), methanol and tert-butyl methyl ether recovered to pattern 1, except 1,1-dimethoxymethane, 1,4-dioxane, 2-ethoxyethanol, 1,1,1,3,3,3-hexafluoro-2-propanol, 2-methyl THF and benzyl alcohol, which all remained amorphous. The high boiling point solvents DMSO, DMA, DMP and NMP were left to continue evaporation. The solids isolated by evaporation of clear solutions of THF and THP showed preferential orientation, but the latter recovered to pattern 1 after grinding.
[0383] Preferential orientation is a commonly observed problem in XRPD experiments, which can occur depending on the crystal size / morphology being analyzed. In normal experiments, crystalline powders have a distribution so that each face of the crystal is analyzed, which ultimately results in an accurate diffraction pattern with peak intensities corresponding to the atoms (electrons) of each crystal face. However, when preferential orientation occurs, only specific faces of the crystal are observed. For example, needles tend to be arranged more like a pack of cigarettes, rather than being randomly distributed. Therefore, certain crystal faces are exposed to X-ray radiation more than others. Therefore, preferential orientation can sometimes lead to diffraction patterns in which only one peak is observed, or the appearance of peaks that are not normally observable. Therefore, gentle grinding of the sample can be used to minimize these potentially misleading effects.
[0384] Based on the solvent solubility evaluation results, 16 solvent systems shown in Table 6 were selected for polymorph screening experiments:
[0385] Table 6 - Solvent systems selected for polymorph screening experiments
[0386]
[0387] The following experiments were performed to identify additional farostat polymorphs: solvent drop milling, rapid cooling, rapid evaporation at 50°C and 100°C (thermal cycling), anti-solvent addition at ambient (room temperature) and elevated temperature (50°C), and a 2-week slurry experiment at 40°C.
[0388] Solvent drop grinding
[0389] 16 x 20 mg samples of Faroxetine DSP polymorph were weighed into 2 mL bead mill vials and milled for 1.5 hours for amorphization. Next, 5 μL of the appropriate solvent (see Table 6) was added to each sample.
[0390] The samples were then bead milled using the following procedure:
[0391] 1. Add 2 stainless steel beads to each vial.
[0392] 2.4500rpm
[0393] 3.10×90 seconds loop
[0394] 4. Hold for 10 seconds between each cycle
[0395] 5. Repeat 4x to get 1 hour grinding time.
[0396] The ground solids were first analyzed by XRPD and compared to the farostat DSP polymorph to check for amorphous patterns. This check step was also performed for other experiments whenever bead milling was performed. Representative XRPD results are shown in Fig.26The XRPD results showed that bead milling of Faloxat generally resulted in less crystalline material. Similar XRPD patterns were observed for post-bead milling inspections performed in other experiments.
[0397] Fig.27A XRPD patterns and Fig.27B Summarize the results.
[0398] The results show that the solids recovered by solvent drop grinding for all 16 solvent systems were restored to pattern 1.
[0399] Thermal Cycling Experiment
[0400] 16 × 20 mg samples of farrustat were first weighed into 2 mL beads and ground to prepare amorphous materials. Appropriate solvents (see Table 6) were added to all 20 beads in 100 μL aliquots until a mobile slurry was obtained without any dissolution being observed. Between additions, the samples were stirred at 40 ° C. The samples were then stirred and the temperature was circulated between 5 and 40 ° C (0.1 ° C / min heating / cooling rate, 1 hour at each temperature) for ~ 72 hours.
[0401] After 48 hours, check the sample. If necessary, add additional solid. The non-flowing solid in the solution sample is stirred with a spatula until a flowing slurry is obtained. The slurry is separated by centrifugation (0.22 μm nylon filter) and the solid is analyzed by XRPD. After the XRPD analysis, the XRPD plate is dried at 40 ° C under vacuum for 48 hours and the solid is analyzed again by XRPD to obtain an indication of the stability of the form.
[0402] Fig.28A shows XRPD results from thermal cycling experiments, and Fig.28B Summarize the results.
[0403] High boiling point solvents such as DMSO, DMA, DMF and NMP were clear solutions and were left to evaporate. After isolation of the solids, the saturates were allowed to evaporate for 72 hours and any recovered solids were further analyzed by XRPD.
[0404] The results show that the solids recovered from the thermal cycling experiments recovered to pattern 1, with the exception of the 1,4-dioxane, THP and THF groups which remained semi-crystalline.
[0405] Room temperature evaporation experiment
[0406] The saturates isolated from the previous thermal cycling experiment were left to evaporate at room temperature. Any solids recovered from the evaporation were analyzed by XRPD. Fig.29A shows XRPD results from thermal cycling experiments, and Fig.29B Summarize the results.
[0407] The results show that individuals obtained from room temperature evaporation of 1,1,1,3,3,3-hexafluoro-2-propanol, 2-methylTHF, DMF, and THF and THP recovered to pattern 1. Solids recovered from 1,1-dimethoxymethane, 1,3-dioxolane, and 1,4-dioxane showed a preferential orientation of pattern 1, but recovered to pattern 1 after grinding.
[0408] Rapid evaporation experiment at 50°C
[0409] 16 x 20 mg samples of farostat were weighed into 2 mL bead mill vials and then ground to prepare amorphous material. To the bead milled sample, a suitable solvent was added in 100 μL aliquots until a mobile slurry was obtained without any observed dissolution. Between additions, the sample was stirred at 50°C and 100°C to dissolve the API in the solvent system, depending on the boiling point of the solvent. The sample was checked and the slurry was separated by centrifugation (0.22 μm nylon filter) and the saturate was placed in an HPLC vial. Next, the vial was uncapped and evaporated at 50°C using a water bath. Finally, after complete evaporation of the solvent, the remaining solid was analyzed by XRPD to check for the appearance of any new pattern.
[0410] FIG. 30A to FIG. 30F shows XRPD results from thermal cycling experiments, and Figure 30G Summarize the results.
[0411] Solids recovered after rapid evaporation of the saturates in 1,3-dioxolane, 1,4-dioxane at 50 °C show preferential orientation. Fig. 30A and Fig. 30B Solids recovered after rapid evaporation of the saturates in 1,1-dimethoxymethane and 2-propanol at 50°C showed an amorphous pattern. Very little solid was obtained from the 2-propanol sample. See Fig. 30C The solids recovered after rapid evaporation of the saturates in THP, THF, 2-methylTHF and 1,1,1,3,3,3-hexafluoro-2-propanol at 50 °C were restored to pattern 1. Fig.30D A potential new pattern was observed in 2-ethoxyethanol, with a new peak at 21.1° 2θ. Fig.30E The solid recovered after rapid evaporation of the saturate in DMF at 50 °C showed pattern 1 with a pronounced preferential orientation. Fig.30F DMA, NMP and DMSO remained in solution.
[0412] Rapid evaporation experiment of high boiling point solvents (DMSO, DMA, DMF and NMP) at 100℃
[0413] 20mg×5 samples of farostat were weighed into 2ml bead mill vials and ground to prepare amorphous materials. A suitable solvent was added to the bead milled sample in 100 μL aliquots until a mobile slurry was obtained without observing any dissolution. Between additions, the sample was stirred at 100°C to dissolve the API in the solvent system. The sample was checked and the slurry was separated by centrifugation (0.22 μm nylon filter) and the saturate was placed in an HPLC vial. The vial was then opened and evaporated at 100°C using a sand bath. After the solvent was completely evaporated, the remaining solid was analyzed by XRPD to check for the appearance of any new pattern.
[0414] Fig.31A and Fig.31B The XRPD results of the flash evaporation experiment at 100°C are shown and Table 7 summarizes the results.
[0415] Table 7 - Summary of the results of the fast evaporation experiments at 100°C
[0416]
[0417] Figure 1 = XRPD pattern of Faroxetine DSP polymorph
[0418] The solid recovered by rapid evaporation of DMA showed a preferential orientation, however it recovered to pattern 1 after grinding. Fig.31A The solid recovered by rapid evaporation of DMF showed a preferential orientation, however it recovered to pattern 1 after grinding. Fig.31B The DMSO and NMP saturates were left to continue evaporation.
[0419] Rapid cooling experiment
[0420] 20mg×16 samples of farostat were weighed into 2ml bead mill vials and ground to prepare amorphous material. Appropriate solvent was added in 100 μL aliquots until a mobile slurry was obtained without any dissolution being observed. Between additions, the sample was stirred at 50°C and 100°C to dissolve the API in the solvent system, depending on the boiling point of the solvent. The sample was checked and the slurry was separated by centrifugation (0.22 μm nylon filter) and the saturated product was placed in a refrigerator for 72 hours. The vial was checked for any solid precipitation. The solid was then separated by centrifugation (0.22 μm nylon filter) and analyzed by XRPD.
[0421] Fig.32A shows the XRPD results from the rapid cooling experiment, and Fig.32B Summarize the results.
[0422] The solids recovered from rapid cooling of 1,3-dioxolane showed a preferential orientation of pattern 1. No solids were obtained after rapid cooling of the other 15 saturates.
[0423] 2-week pulping experiment
[0424] 16 x 20 mg samples of farostat were weighed into 2 mL vials and bead milled to prepare amorphous material. For milling, the following protocol was followed:
[0425] • Place 2 stainless steel beads into each vial.
[0426] 5000rpm
[0427] ●10×90 seconds loop
[0428] Hold for 10 seconds between each cycle
[0429] • Repeat 6x to give 1.5 hours grinding time.
[0430] The ground sample was analyzed by XRPD as usual to check for amorphous patterns. Next, the desired amount of a suitable solvent was added to the ground sample to prepare a white slurry. The vial was sealed with paraffin and stirred isothermally at 40°C for 2 weeks. After 2 weeks, the slurry was observed and the isolated solid was characterized by XRPD. Any clear solution was left to evaporate at 100°C and any solid recovered was further analyzed by XRPD.
[0431] Fig.33A XRPD results from a 2 week slurry experiment are shown. Fig.33B Shown are XRPD results from a 2 week slurry experiment of samples subjected to flash evaporation at 100°C. Fig.33C Summarizes the results from the entire 2-week slurry experiment.
[0432] The results show that solids recovered from 2-week slurry experiments of 93% ethanol:7% water (% v / v), 48% methanol:52% water (% v / v), 2-propanol, and 2-methyl THF recovered Pattern 1. Solids recovered from THF and THP showed Pattern 1 with an additional peak at 8.1° 2θ (Pattern 1+).
[0433] Solids obtained from 1,1-dimethoxymethane, 1,3-dioxolane, 2-ethoxyethanol and 1,1,1,3,3,3-hexafluoro-2-propanol, DMA, DMF and NMP showed preferential orientation after rapid evaporation at 100° C. However, these recovered to pattern 1 after grinding.
[0434] Antisolvent addition experiments (acetone, heptane, MEK and water)
[0435] 20mg×16 Faroxetine samples were weighed into 2ml bead mill vials and ground to prepare amorphous materials. Appropriate solvents were added in 100 μL aliquots until a mobile slurry was obtained without any dissolution being observed. The sample was stirred at high temperature (40°C). The sample was checked and the slurry was separated by centrifugation (0.22 μm nylon filter) and the saturates were separated into 4 different vials. At room temperature, water, MEK, acetone and heptane as anti-solvents were added to each vial to check for any solid precipitation. The solids were then separated by centrifugation (0.22 μm nylon filter) and analyzed by XRPD.
[0436] The results are shown in Fig.34A and Fig.34C and outlined in Fig.34B and FIG. 34D to FIG. 34F middle.
[0437] With the exception of 2-methylTHF, 2-propanol, 48% methanol:52% water (% v / v), 93% ethanol:7% water (% v / v), and benzyl alcohol, which remained clear solutions, the solids recovered from water added as antisolvent recovered to Pattern 1. Fig.34A .
[0438] The solid recovered by adding acetone as antisolvent recovered pattern 1 for 1,1,1,3,3,3-hexafluoro-2-propanol along with an additional peak, which may be due to the splitting of the peak due to preferential orientation. Fig.34C .
[0439] Turbid solutions were observed in 1,1-dimethoxymethane and 1,2-dioxolane after heptane addition.No solid precipitation was observed for any of the other 14 solvent systems after heptane addition.
[0440] No solid precipitation was observed after MEK addition for any of the 16 solvent systems tested.
[0441] Antisolvent addition + rapid cooling experiment
[0442] All clear solutions obtained from previous anti-solvent addition experiments were placed in a refrigerator for rapid cooling. After 72 hours, samples were checked and the solid precipitate was isolated by centrifugation (0.22 μm nylon filter) before being reanalyzed by XRPD.
[0443] Only the sample using MEK as anti-solvent in 1,4-dioxane produced a white solid after rapid cooling and was analyzed by XRPD. The XRPD results are shown in Fig.35 The indicated samples had an XRPD pattern consistent with Pattern 1. All other fast cooled samples remained clear solutions.
[0444] Antisolvent addition at high temperature (50°C)
[0445] 20mg×16 Faroxetine samples were weighed into 2ml bead mill vials and ground to prepare amorphous materials. Appropriate solvents were added in 100 μL aliquots until a mobile slurry was obtained without any dissolution being observed. The sample was stirred at high temperature (40°C). Next, the sample was checked and the slurry was separated by centrifugation (0.22 μm nylon filter) and the saturate was transferred to an HPLC vial. At 50°C, water as an anti-solvent was added to each vial to check for any solid precipitation. The solids were then separated by centrifugation (0.22 μm nylon filter) and analyzed by XRPD.
[0446] The results are shown in Fig.36A and outlined in Fig.36B The results show that the solids obtained from the addition of water at 50°C to all 16 saturates recovered to pattern 1.
[0447] in conclusion
[0448] Most solids recovered from the solvent systems tested produced XRPD patterns consistent with that of the farostat DSP polymorph (Pattern 1). Thus, the above experiments provide additional evidence that the presently disclosed farostat DSP polymorph is highly stable.
[0449] Example 9 - Characterization of Faroxetine Polymorphs
[0450] The solids recovered from THF and THP in the 2-week slurry experiment showed pattern 1 with an additional XRPD peak at 8.1° 2θ (pattern 1+). In view of this interesting observation, the 2-week slurry experiment was repeated. As a result of the experiment, two new polymorphs of faroxetine were identified:
[0451] Faroxetine polymorphs obtained by crystallization from 1,1,1,3,3,3-hexafluoro-2-propanol (HIFP)
[0452] In a 1.5 mL HPLC vial equipped with a magnetic stir bar, 500 μL of 1,1,1,3,3,3-hexafluoro-2-propanol was added to 20 mg of amorphous farrustat DSP polymorph, resulting in the formation of a mobile slurry. The slurry was stirred isothermally at 40 °C for 2 weeks. When it became a clear solution after 1 week, another 20 mg of material was added to the slurry. The solid was isolated by centrifugation using a 0.22 μm nylon filter and analyzed by XRPD, TGA and 1 H NMR (proton nuclear magnetic resonance) analysis was performed without any further drying. Finally, the sample was dried at 40°C for 4 hours and then analyzed again by XRPD.
[0453] The XRPD results are shown in Fig.37 In. Fig.37As can be seen, a clear new XRPD pattern was observed for 1,1,1,3,3,3-hexafluoro-2-propanol (referred to herein as Pattern 2). However, gentle drying at 40°C for 4 hours restored the XRPD pattern to that of the farostat DSP polymorph (Pattern 1). Fig.38 The XRPD peak list for Pattern 2 is shown.
[0454] Fig.39A and Fig.39B The results of TG analysis are shown. TG analysis indicated a mass loss of 0.118 mg (5.59%), which corresponds to 0.13 equivalents of hexafluoro-2-propanol. At the same time, DSC analysis indicated an endothermic event consistent with the melting of pattern 1. This indicates that the new 1,1,1,3,3,3-hexafluoro-2-propanol polymorph is a metastable form, which is easily restored to the farostat DSP polymorph after drying at 40°C for 4 hours.
[0455] Fig.40A and Fig.40B Each shows the 1H NMR spectrum of the 1,1,1,3,3,3-hexafluoro-2-propanol polymorph before drying (wet) and after drying. Fig.40A The NMR spectrum of indicated the presence of an additional peak at 5.15 ppm (the methine protons of HFIP). The data overall also indicated that the 1,1,1,3,3,3-hexafluoro-2-propanol polymorph appeared to be a monosolvate.
[0456] Fig.41A and Fig.41B Each shows the FR-IR spectrum of the 1,1,1,3,3,3-hexafluoro-2-propanol polymorph relative to the FR-IR spectrum of the farostat DSP polymorph. As can be seen, the FR-IR spectra are clearly different between the two samples.
[0457] The difference in solvent content between TGA and NMR analysis is explained at least in part by the characteristics of the analytical method. In this regard, TGA uses a nitrogen stream on the sample during analysis. This appears to be sufficient to partially desolvate the 1,1,1,3,3,3-hexafluoro-2-propanol polymorph. In contrast, in NMR, the entire sample is dissolved in the NMR solvent and added to the NMR tube. Therefore, the entire sample and the 1,1,1,3,3,3-hexafluoro-2-propanol solvent will be included in the subsequent analysis.
[0458] In summary, the data provide evidence that the polymorph obtained from 1,1,1,3,3,3-hexafluoro-2-propanol is a new but unstable polymorph pattern for farostat.
[0459] Faroxetine polymorphs obtained by crystallization from N-methylpyrrolidone (NMP)
[0460] In a 1.5 mL HPLC vial equipped with a magnetic stirring bar, 350 μL of N-methylpyrrolidone (NMP) was added to 20 mg of amorphous farrustat DSP polymorph to prepare a mobile slurry. The resulting slurry was thermally cycled between 5 and 40° C. for 3 days (ramp rate: 0.1° C. / min and isothermal hold at 40° C. and 5° C. for 1 hour). The saturated solution was then evaporated at 100° C. before solid analysis by XRPD.
[0461] The XRPD results are shown in Fig.42 The XRPD diffraction pattern of the evaporated solid (herein referred to as Pattern 3) shows Pattern 1 with additional peaks at 15.28°2θ, 17.73°2θ, 18.48°2θ, 23.13°2θ, 24.60°2θ, 25.96°2θ and 29.90°2θ, indicating the presence of a mixture of the Faroxerstat DSP polymorph and another new polymorph pattern. Gentle grinding does not change the observed pattern. However, drying at 40°C for 4 hours causes Pattern 3 to transform back to Pattern 1 (i.e., the XRPD pattern of the Faroxerstat DSP polymorph).
[0462] Fig.43 Displays the peak list for Pattern 3. Prominent peaks are additional peaks observed in addition to the Pattern 1 peaks.
[0463] The results of TG analysis are shown in Fig.44 The analysis showed a mass loss of 0.048 mg from the onset of heating, which corresponds to 0.07 equivalents of NMP.
[0464] The results of NMR analysis are shown in Fig.45 The 1H NMR spectrum showed multiple peaks at 2.06 ppm and 1.96 ppm, which corresponded to 0.2 equivalents of NMP solvent present in the tested sample.
[0465] In summary, the above data demonstrate that a potential new polymorph of farostat can be obtained by crystallization from NMP. At this point, the new polymorph has not been isolated in pure form, but instead is obtained as a mixture with the farostat DSP polymorph. However, given that gentle heating at 40°C for 4 hours is sufficient to restore Pattern 3 to Pattern 1, this new polymorph (such as 1,1,1,3,3,3-hexafluoro-2-propanol polymorph) may be unstable / metastable.
[0466] in conclusion
[0467] These experiments demonstrated that new polymorphs of farostat can be obtained by crystallization from the solvents 1,1,1,3,3,3-hexafluoro-2-propanol and NMP (see Fig.46). However, the data indicate that these new polymorphs have a high tendency to revert to the farostat DSP polymorph, thus further confirming that the farostat DSP polymorph that has been successfully produced and identified has high stability.
Claims
1. A polymorph of the DHODH inhibitor 2-(3,5-difluoro-3'-methoxybiphenyl-4-ylamino)nicotinic acid, such as a crystalline polymorph, characterized by an X-ray powder diffraction pattern comprising peaks corresponding to 2-theta angles at approximately the following positions: 9.129±0.1, 17.375±0.1, 20.708±0.1, 25.274±0.1, 26.488±0.1, and 29.041±0.
1.
2. The polymorph of claim 1, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 13.686±0.1, 14.159±0.1, 19.900±0.1, 21.431±0.1, 22.750±0.1, 25.607±0.1 and 30.893±0.
1.
3. The polymorph of claim 1 or 2, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 12.313±0.1, 13.223±0.1, 18.167±0.1, 22.146±0.1, 23.418±0.1, 23.828±0.1, 25.885±0.1, 27.219±0.1 and 30.612±0.
1.
4. The polymorph of any one of claims 1 to 3, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 10.645±0.1, 27.453±0.1, 29.762±0.1, 31.743±0.1, and 39.115±0.
1.
5. The polymorph of any one of claims 1 to 4, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 14.580±0.1, 28.368±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, and 38.520±0.
1.
6. The polymorph of any one of claims 1 to 5, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 12.313±0.1, 13.223±0.1, 13.686±0.1, 14.159±0.1, 16.477±0.1, 18.167±0.1, 19.900±0.1, 21.431±0.1, 22.146±0.1, 22.750±0.1, 23.418±0.1, 23.828±0.1, 25.607±0.1, 25.885±0.1, 27.219±0.1, 30.612±0.1, and 30.893±0.
1.
7. The polymorph of any one of claims 1 to 6, wherein the X-ray powder diffraction pattern further comprises one or more peaks selected from the group consisting of 10.645±0.1, 14.580±0.1, 27.453±0.1, 28.368±0.1, 29.762±0.1, 31.743±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, 38.520±0.1, and 39.115±0.
1.
8. The polymorph of any one of claims 1 to 7, wherein the X-ray powder diffraction pattern further comprises the following peaks: 9.129±0.1, 10.645±0.1, 12.313±0.1, 13.223±0.1, 13.686±0.1, 14.159±0.1, 14.580±0.1, 16.477±0.1, 17.375±0.1, 18.167±0.1, 19.900±0.1, 20.708±0.1, 21.431±0.1, 22.146±0.1, 22.750±0.1, 23.418±0.1, 23.828±0.1, 25.274 ±0.1, 25.607±0.1, 25.885±0.1, 26.488±0.1, 27.219±0.1, 27.453±0.1, 28.368±0.1, 29.041±0.1, 29.762±0.1, 30.612±0.1, 30.893±0.1, 31.743±0.1, 32.950±0.1, 33.445±0.1, 33.800±0.1, 34.936±0.1, 35.497±0.1, 35.981±0.1, 37.678±0.1, 38.099±0.1, 38.520±0.1 and 39.115±0.
1.
9. The polymorph as claimed in any one of the preceding claims, characterised by an X-ray powder diffraction pattern as shown in Figure 2.
10. A composition comprising a polymorph as claimed in any one of the preceding claims and a pharmaceutically acceptable excipient, diluent or carrier.
11. A polymorph as claimed in any one of claims 1 to 9 or a composition as claimed in claim 10 for use in therapy.
12. The polymorph or composition for use according to claim 11, wherein the treatment is for a viral disease or an autoimmune disease.
13. The polymorph or composition for use as claimed in any one of claims 11 to 12, wherein the virus is selected from the group comprising dengue (such as serotype 1, 2, 3 or 4), Zika, Chikungunya and SARS-CoV-2.
14. The polymorph or composition for use according to any one of claims 12 to 13, wherein the autoimmune disease is selected from the group comprising multiple sclerosis, rheumatoid arthritis and inflammatory bowel disease (such as ulcerative colitis and Crohn's disease).
15. The polymorphic form or composition for use according to claim 12, wherein the autoimmune disease is an autoimmune skin disease, for example selected from the group comprising: vitiligo, alopecia, atopic dermatitis, Behcet's disease, dermatitis herpetiformis, dermatomyositis, lichen planus, linear IgA disease, cutaneous lupus, morphea / scleroderma, ocular cicatricial pemphigoid, pemphigoid (such as bullous pemphigoid or gestational pemphigoid), pemphigus (such as pemphigus vulgaris, pemphigus foliaceus, pemphigus erythematosus, IgA pemphigus, pemphigus vegetative or paraneoplastic pemphigus), vasculitis, epidermolysis bullosa acquisita, psoriasis and bullous dermatoses.
16. The polymorphic form or composition for use according to claim 15, wherein the autoimmune skin disease is selected from the group comprising: vitiligo, such as segmental or non-segmental vitiligo; and alopecia, such as diffuse alopecia areata, monolocalized alopecia areata, creeping alopecia areata, barbaric alopecia, alopecia totalis or universalis.
17. Use of the polymorph according to any one of claims 1 to 9 or the composition according to claim 10 in the manufacture of a medicament for treating viral infection or autoimmune disease.
18. A method for treating viral infection or autoimmune disease, comprising administering a therapeutically effective amount of the crystalline form according to any one of claims 1 to 9 or the composition according to claim 10 to a subject in need thereof.
Citation Information
Cited By
Application of Fardodstat in preparation of medicine for preventing or treating cerebral ischemia-reperfusion injury
CN120514705A
